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Abstract
This project investigated an anti-staphylococcal bacteriophage-derived peptidoglycan
hydrolase enzyme, namely a cysteine-histidine amydohydrolase/peptidase (CHAPk). The
study focused firstly on optimizing the production of recombinant CHAPk, which was
previously cloned in an E. coli expression system, and sets out the resulting optimal Standard
Operating Procedures (SOPs) for production, purification and determination of concentration
and activity of the resulting protein stock. A typical yield resulting from the investigation was
300pg of CHAPk from one litre of E.coli culture. The activity of the purified enzyme was
typically in the region of 190U nmol ’. Secondly, the project investigated the application of
CHAPk to eliminate S. aureus from blood. It was found that concentrations of 200 and lOOpg
mP' of the enzyme eliminated S. aureus DPC5246 (2.5 x lO”' CPU ml ') within 30 minutes
and one hour, respectively. In the third and final part of the project, the gene encoding
CHAPk was cloned into the Lactococcus /c/crA-derived vector pNZ44 with the aim of
introducing it into a probiotic Lactobacillus strain as a model for secretion of endolysins in
lactic acid bacteria. This vector uses the pediocin operon to drive the secretion of
recombinant protein. A variety of cloning strategies were investigated.

Chapter 1

Literature review

1. Introduction
Bacteriophages, or phages, are viruses that invade bacterial cells. In the case of
virulent phages, infection results in the lysis of infected cells (Sulakvelidze et ah, 2001).
These phages represent a potential alternative to antibiotics for the treatment of antibioticresistant bacterial infections (Matsuzaki et ah, 2005). Cell lysis is genetically mediated by
phage-encoded peptidoglycan hydrolases called endolysins (lysins). Non-filamentous phages
use lysins to either inhibit the synthesis of peptidoglycan (encoded by single-stranded phage
DNA/RNA) or to break the chemical bonds in the peptidoglycan of bacterial cells (encoded
by double-stranded phage DNA) using a complex holin-endolysin system (Borysowski et al.,
2006). Holins are small proteins that form pores in the plasma of bacterial cells and allow
endolysins to reach their target in the peptidoglycan, resulting in the lysis and release of
phage progeny (Young et al., 1992) at a specifie time, which is referred to as the “lysis cloek”
(Shi et al., 2012). When lysins are cloned and produced in a recombinant manner, they may
be used exogenously, and as such, the holin is not needed. This is also referred to as “lysis
from without” (Molineux et al., 2006). As sueh, these enzymes have found application for the
elimination of Gram-positive bacteria because, unlike Gram-negatives, there is no outer
membrane to prevent access to the peptidoglycan.
As a general rule, endolysins present a two domain modular strueture comprised of an
N-terminal catalytie domain and a C-terminal binding domain. The catalytic domain varies
by its lytic action toward either the cell wall or the peptidoglyean of bacteria. There are four
different types of aetivity (Fig. 1):
L-alanoyl-D-glutamate

endopeptidases

and

interpeptide

bridge-specific

endopeptidases cleave the peptide moiety of the bacterial peptidoglycan;
N-acetylmuramoyl-L-alanine amidases cut the amide bonds between the sugar and
peptide moieties of the cell wall;
N-acetyl-(3-D-glucosaminidases, or glucosidases, cut the 1,4-p glycosidic bond
between sugar moieties of the cell wall;
N-acetylmuramidases, also called lysozymes.

Figure 1. Scheinatic representation of bacterial peptidoglycan arrangement with the corresponding
target sites: (1) endopeptidases, (2) amidase, (3) glycosidase, (4) muramidases. (To date,
endopeptidase activity has only been reported with Gram-positives).

It has been demonstrated that a number of reported endolysins have a chimeric conformation
with two different catalytic domains (Tables 1, 2, 7, 8) and with or without a cell wall
binding domain (Mishra et ah, 2013; Rodriguez-Rubio et ah, 2012; Schmelcher et ah, 2012;
Lim et al., 2012; Gu et ah, 201 la, 201 lb; Jun et ah, 2011; Wang et ah, 2009; Obeso et al.,
2008; Pritchard et al., 2007, 2004; Donovan et al., 2006; O’Flaherty et al., 2005; Cheng et al.,
2005; Yokoi et al., 2005; Varea et al., 2004). Most of the cloned endolysins with two
catalytic domains were from staphylococcal phages with a combination of an endopeptidase
and an amidase as the N-terminal of the protein.
The cell wall binding domain of endolysins facilitates bringing the enzymatic
domains to their site of action. The Cpl-1 lysin was the first enzyme whose crystal structure
was established (Monterrosso et al., 2002). Efficient cell lysis occurs when choline is
recognised by the choline binding domain of Cpl-1 lysin, allowing the correct orientation of
the catalytic domain for lytic activity. Another lysin, Cpl-7, harbours a C-terminal binding
domain comprised of a three- repeated tandem of 42 amino acids that bind to either cholineor ethanolamine-containing cell walls of pneumococci (Bustamante et al., 2012). However,
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after purification, a number of enzymes were found to be more active without their native cell
wall-binding domain (Briers et ah, 2008; Cheng et ah, 2006; Loessner et ah, 1998).
Truncated versions of endolysins comprised solely of the catalytic domains have been
reported for both lysins LysK (cysteine, histidine-dependent amidohydrolase/peptidase or
CHAP) (Horgan et ah, 2009) and CD27L (Mayer et ah, 2011). Both were demonstrated to
have a higher lytic activity while retaining specificity for its host and resulting in a broader
range of activity, respectively. This suggests that the binding domain forces the catalytic
domain to get into a certain conformation and restricts it to a specific location on the
peptidoglycan (Low et ah, 2005). Recent studies reported the existence of Gram-negative
endolysins, a number of which have a modular structure that is different from those of Grampositives. Their catalytic domain is situated at the C-terminal end of the protein and their
binding domain is at the N-terminus (Walmagh et ah, 2012; Briers et ah, 2009).
The different exogenous applications of phage endolysins from both Gram-positive
and Gram-negative bacteria are explored in this review. Their muralytic properties will be
discussed based on their spectrum of activity, in vivo activity in mouse models and activity in
synergy with a different antimicrobial agent or another endolysin. In addition, the review will
explore endolysin engineering to improve enzyme activity and/or specificity.
2. Endolysins against pathogenic Gram-positive bacteria.

2.1. Streptococcus species.
During the last 45 years, Vincent Fischetti and colleagues made a major contribution
to streptococcal genetics; he has also been a pioneer in the area of phage endolysins from
streptococci and other genera (Fischetti et ah, 1968a, 1968b). This group studied most of the
endolysins described in Table 1, with a number of endolysins reported to date to be active in
vivo in murine models with promising results. Streptococci are responsible for septicaemia,
necrotising fasciitis, pharyngitis, rheumatic fever (Group A streptococci, GAS) (Kaplan et ah,
2011), meningitis and pneumonia in newborns (Group B streptococci, GBS) (Pettersson,
2007; Rajagopal, 2009).

Table 1. Synopsis of key characteristics of cloned streptococcal endolysins.

Ori^jin

Name

Number
of
catalytic
domains

Activity

Presence
of cell
wall
binding
domain

Studied
in vivo

Reference

S. pneumoniae <l)Dp-l

Pal

2

amidase,
endopeptidase

+

+

Loeffler et al., 2001

S. pneumoniae OCpl-l

Cpl-1

1

muramidase

+

+

Loeffler et al., 2003

S. agalactiae 0830

GBS
lysin

2

muramidase,
endopeptidase

+

-

Pritchard et al.,
2004

GBS O NCTC 11261

PlyGBS

2

muramidase,
endopeptidase

+

-1-

Cheng et al., 2005

S. uberis (ATCC
700407)

Ply700

1

putative amidase

+

-

Celia et al., 2007

S. agalactiae >^Sal
prophage

LSal
lysin

1

glycosidase

+

-

Pritchard et al.,
2007

-S’, agalactiae kSa2
prophage

kSa2
lysin

2

glycosidase,
endopeptidase

+

-

Pritchard et al.,
2007

.S’, pyogenes OC1

PlyC

1

amidase

+

+

Hoopes et al., 2009

.S’. r;ra//.vCl)FH10

()RF3.S

1

muramidase

+

-

.S’, pneumoniae U)CF-7

Cpl-7

1

muramidase

+

-

Van der Ploeg et
al., 2010
Bustamante et al.,
2012

.S’. ,vwA89/1591
prophage serotype 2

PlySs2

1

endopeptidase

-1-

+

Gilmer et al., 2013

Among streptococcal endolysins, four have been taken to the in vivo stage in terms of
their activity. Several other scientists have also made important contributions in the
identification and characterisation of additional endolysins. Recently, lysin PlySs2 has been
characterised at the in vivo stage; the enzyme demonstrated a high potential for use as a
therapeutic agent. A survival rate of 89% and 94% occurred with MRSA- and S. pyogenesinfected mice, respectively, using a single dose of PlySs2 enzyme (4mg ml ') (Gilmer et al.,
2013). Also, the endolysin PlySs2 has been demonstrated to be effective against strains from
two different bacterial orders, namely Bacillales {Staphylococcus, Listeria, etc.) and
Lactohacillales {Streptococcus, Enterococcus, etc.), which can be explained by the similar
peptidoglycan structure shared by these bacteria (Schleifer et al., 1972). Lysins Cpl-1 and Pal
were effective in murine models for the elimination of antibiotic-resistant S. pneumoniae.
Lysin Cpl-1 has been widely studied in different situations in vivo. Loeffler et al. (2003)
injected a 2000pg-dose of Cpl-1 enzyme intravenously an hour post-infection in artificially-

infected mice. This amount of enzyme reduced the S. pneumoniae cell titre to undetectable
levels within 15 minutes. Subsequent studies on Cpl-1 enzyme proved its ability to prevent
endocarditis and meningitis (Grandgirard, 2008; Entenza et ah, 2005). In another study from
Witzenrath and colleagues (2009), lysin Cpl-1 was injected into the peritoneum of mice 24h
after infection by S. pneumoniae. All mice treated with the Cpl-1 enzyme survived and
recovered. Loeffler et al. (2001) demonstrated that lysin Pal was able to kill S. pneumoniae
cells from nasopharynx of mice. Similarly to lysins Cpl-1 and Pal, lysins PlyC and PlyGBS
were studied in vivo against Group A streptococci (GAS), inducers of pharyngitis and
rheumatic fever (Nelson et ah, 2001), and Group B streptococci (GBS), responsible for
vaginal colonisation inducing meningitis and sepsis in newborns (Cheng et ah, 2006). Firstly,
a lOng-dose of PlyC enzyme was sufficient to kill a culture of 10^ CPU GAS. Subsequently,
samples from infected-mice 24h after injection of lysin PlyC demonstrated total elimination
of streptococci (Hoopes et ah, 2009) and also of GAS biofilm (Shen et ah, 2013). In a similar
way, lysin PlyGBS significantly reduced GBS cell titre in vaginally-challenged mice. This
enzyme had no toxicity against normal human vaginal bacterial flora (Cheng et ah, 2005).
The veterinary area is also being considered for future application for phage
endolysins. S. equi causes equine strangles which can have a mortality rate of 8% in horses
(Sweeney et ah, 1987). Prevention of infections by S. equi involves sanitisation of equipment
in contact with infected animals in addition to hygiene standards. Lysin PlyC was reported to
be effective against a number of different clinical isolates of S. equi. Indeed, 1 pg of enzyme
was able to kill a 10 CPU ml' culture in 30 minutes. Sanitisation of equipment requires the
use of liquid-based/spray disinfectants. Lysin PlyC used in aerosol demonstrated its lytic
potential by eliminating S. equi bacterial load on surfaces in the presence of organic
materials, similarly to real conditions (Hoopes et ah, 2009).
In general, streptococcal endolysins have been demonstrated to have significant
promise in human and veterinary applications. These include both therapeutic and
prophylactic approaches.
2.2. Staphylococcus aureus
Staphylococcus aureus belongs to the normal human bacteriological flora which can
be found either on the skin or in the nose without causing infection. The increased concern
related to infections by this organism relates to its resistance to antibiotics and also its ability
to form biofilms. Infection can potentially result in fatal invasive disease for the patient
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(Worby et al., 2013; Webb et al., 2010; Harris et al., 2010; Klevens et al., 2007), hence the
necessity to find complimentary antibacterial agents, such as phages or phage endolysins. A
variety of endolysins cloned from staphylococcal phages have been studied to date and these
are described in Table 2.
Table 2. Synopsis of key characteristics of cloned staphylococcal endolysins.

Origin

Name

Number of
catalytic
domains

Activity

S. aureus 0187

Ply 187

1

amidase

S. aureus OMR 11

MV-L

2

S. warneri M OWMY

LysWMY

S. aureus OP68

Presence of
cell wallbinding
domain

Studied
in vivo

Reference

Non-specified

-

Loessner el al., 1999

amidasc, endopeplidase

-

-1-

Malsuzaki el al., 2003

2

amidase, endopeplidase

-KSH3b)

-

Yokoi el al., 200,3

Lys 16

1

endopeplidase

(SH3h)

-

Takac el al., 2005

.S', aureus OK

LysK
(CHAPO

2

amidase, endopeplidase

+ (SH3b)

-t-

O'Flahenyel al., 2005

S. aureus 011

011 lysin

2

amidase, endopeplidase

+ (SH3b)

-

Donovan el al., 2(X)6

S. aureus OH.S

LysH.S

2

amidase, endopeplidase

-1- (SH3b)

-

Obe,so el al., 2008

(l)Twoil + <1)NM.7

ClyS

1

amidase

+

-t-

Daniel el al., 2010

-S’, aureus <])GH 1 .S

Ly.sGHI.S

2

amida.se, endopeplidase

+ (SH.3b)

+

Gu el al., 2011

S’, aureus OP-27/HP

P-27/HP

Non-speciriecl

Non-specified

Non-specified

-1-

Gupla el al., 2011

S. aureus OvB_SauSPLA88

HydH.S

2

glycosidase,
endopeplidase

-

-

Rodriguez el al., 201 1

S. aureus <I)SAP-I

SAL-1

2

amidase, endopeplidase

-1- (SH.3b)

'

Jun el al., 201 1

S. aureus OSH2

SH2

2

amidase, endopeplida.se

+ (SH3b)

-

Schmelcher el al., 2012

S', aureus 087

Lys87

1

endopeplidase

Non-specified

*

Fernandes el al., 2012

S. aureus OSA4

LysSA4

Non-specified

Non-specified

Non-specified

■

Mishra el al., 2013

While the majority of the endolysins in Table 2 have been well characterised, a
number of these have been applied in vivo with promising results. The muralytic capacity of
an enzyme is the first step in the recognition of a potent antibacterial agent. Endolysins MVL, P-27/HP and LysGHlS have been tested in vivo in murine models. Lysin P-27/HP (Gupta
et al., 2011) demonstrated an interesting muralytic activity as 99.9% of staphylococcal cells
identified in spleen samples from mice were killed, whereas Lysin MV-L (Rashel et al.,
2007) was able to completely kill staphylococcus cells from mice nasal cavities. Mice
infected with 7 x lO'^ CPU MRS A were treated one hour post-infection with endolysin
LysGH15. A 50pg dose of this enzyme was sufficient for infected-mice to survive (Gu et al..
8

2011). In addition, endolysin LysGH15 demonstrated a noticeable capacity to reduce
inflammation phenomenon in MRSA-infected mice by reducing the levels of cytokines.
Indeed, a 200pg-dose of endolysin LysGH15 had no toxicity towards mice. According to
Table 2, a number of these endolysins have been subjected to protein engineering prior to in
vivo applications. For example, the truncated construct of endolysin LysK, namely CHAPk,
has been successfully studied in vivo in murine nasal cavities. In general, these enzymes
demonstrated efficacy in eliminating MRSA strains. Also, the truncated construct of
endolysin LysK and the enzymes SAL-2 and 011 have demonstrated to be efficient against S.
aureus biofilms, which is a current issue in healthcare surroundings (Fenton et al., 2013; Son
et al., 2010; Sass et al., 2007).
Raw milk is frequently used for the manufacturing of cheeses and can contain high
levels of staphylococci. While levels of 10'^ CFU mb' are tolerated, it is nevertheless
desirable to keep the level under control. Milk has also been subject to treatments with
endolysins to eliminate staphylococci, which are prevalent. In this context, endolysins SH2
and LysH5 were tested in milk-conditions and in actual milk, respectively. Muralytic activity
of lysin SH2 was improved by the addition of different concentrations of Ca"”^, one of the
major constituents of milk, by 3-fold (lOmM) and its truncated derivative (N-terminal
catalytic domain: cysteine, histidine-dependent amidohydrolase/peptidase or CHAP) by 6fold (ImM) (Schmelcher et al., 2012) against MRSA. Also, lysin LysH5 minimum inhibitory
concentration (MIC) against MRSA was reduced to 50U mb’ in the presence of Ca^"^ (23mM) (Garcia et ab, 2010). Such data encourage the application of endolysins in food
preservation. However, this study was applied to pasteurised milk, which obviously does not
contain staphylococci, artificially infected with S. aureus. It is noteworthy that endolysin was
not capable of eliminating S. aureus from raw milk, where it presents a problem.
Anti-staphylococcal endolysins reported to date present a very similar structure with
two catalytic domains and a cell wall binding domain (Table 2). However, the endolysin MVL (Rashel et ab, 2007), as well as the virion-associated peptidoglycan hydrolase HydH5
(Rodriguez-Rubio et ab, 2012; Rodriguez et ab, 2011), have two catalytic domains but no
recognised cell wall-binding domain. Different fusions of a specific cell wall-binding domain
to one of these native enzymes have been carried out. In some cases, their muralytic activity
against MRSA from the resulting constructs has been improved.

2.3. Listeria monocytogenes
Listeria monocytogenes is ubiquitous in the environment (Weis et al., 1975; Ivanek et
al., 2006). Listeria species grow at low temperatures under inconvenient conditions, such as
low pH and high salt concentrations (Hudson et al., 1994). Such characteristics suggest that
Listeria species can contaminate and grow in meat-based and dairy-based manufactured
ready-to-eat foods. The major clinical symptoms of Listeria monocytogenes infections are
indicated by gastroenteritis, meningitis, septicaemia and meningoencephalitis (Kreft et al.,
2001; Schuchat et al., 1997). However, the likeliness of such an infection occurring is
estimated at 0.1-1.1 cases per 10*' people (Drevets and Bronze, 2008). To date, six endolysins
for this important pathogen have been described (Table 3).
Table 3. Synopsis of key characteristics of cloned Listeria endolysins.

Name

Activity

Presence of
cel! wall
binding
domain

Target

Fly.SOO

endopeptidase

+

serovar
1/2,3,4.5.6.7 strains

Kretzer et al.,
2007

FlyF.lS

amidase

+

serovar 1/2,3
strains

Eugster et al.,
2011

FlyF4()

amidase

+

A1Y mu rein

Eugster et al.,
2012

L. monocytogenes
OA1 18

Flyl 18

amidase

+

Aly murein

Eugster et al.,
2012

L. monocytogenes
a)A5()()

Fly.SI 1

amidase

-f-

Aly murein

Eugster et al.,
2012

L. monocytogenes
(DFWLLrn?

LysZ.S

amidase

Nonspecified

Non-specified

Zhang et al.,
2012

Origin

L monocytogenes
(DASOO

L. monocytogenes

L. monocytogenes OF4()

Studied
III VIVO

..
Reference

None of the reported endolysins have been studied in vivo to date, but one of these
enzymes has been tested in soya milk, namely lysin LysZ5 (Zhang et al., 2012). A lysin
concentration of 40Lf ml ' was added to artificially-infected soya milk, which resulted in a 5logio CPU mb' reduction in L. monocytogenes cell titre. Lysin LysZ5 was also effective
against other species. The group of Loessner also exploited the cell wall binding domains of
Listeria endolysins. Lysins PlySOO and PlyP35 (Eugster et al., 2011) both have a binding
domain that target the cell wall-linked teichoic acids of L. monocytogenes cells serovar 4, 5, 6
and serovar 1/2, 3 respectively. Lysins Plyl 18, Ply511 and PlyP40 can only bind to the Aly-
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chemotype peptidoglycan of L. monocytogenes cells (Eugster et al., 2012), which is a
common feature in Gram-negative bacteria. The cell wall-binding domain of PlyllS and
PlySOO were coated on paramagnetic beads in order to eapture and immobilise L.
monocytogenes cells from food homogenates (Kretzer et ah, 2007). More than 90% of L.
monocytogenes cells were attached and immobilised from the homogenates after 48 hours. In
these experiments, the cell wall-binding domain was fused to Green Fluorescent Protein, thus
enabling clear detection of Listeria in the food product. Another food application of a Listeria
endolysin was also demonstrated by the group of Loessner, where the enzyme was eloned
into a Lactococcus lactis under the control of a secretion system where it reduced the level of
Listeria monocytogenes in some cases (Turner et al., 2007; Gaeng et al., 2000).
2.4. Bacillus species
Bacillus species are Gram-positive spore-forming baeteria comprised of two
pathogens, namely B. cereus (food intoxication) and B. anthracis (anthrax).
Table 4. Synopsis of key characteristics of cloned Bacillus endolysins which have a broad spectrum of
activity.
Name

Number of
catalytic
domains

Presence of cell
wall-binding
domain

Studied
in vivo

Reference

B. cereus OBastille

PlyBa

N on-specified

Non-specified

-

Loessner et al., 1997

B. cereus O12826

Ply 12

1

amidase

+

-

Loessner et al., 1997

B. cereus OTP21

Ply21

1

amidase

-1-

-

Loessner et al., 1997

B. anthracis Oy

PlyG

1

amidase

-t-

-1-

Schuch et a!., 2(X)2

B. anthracis Ames
strain

PlyPH

1

amidase

-1-

-t-

Yoong et al., 2006

B. anthracis OBcpl

PlyB

1

muramidase

Non-specified

-

Porter et al., 2007

B. thuringiensis
OBtCS33

PlyBt33

1

amidase

-t-

-

Yuan et al., 2012

B. cereus OBPS13

LysBPSI3

I

amidase

+

-

Park et al., 2012

B. cereus OB4

LysB4

1

endopeptidase

+

-

Son et al., 2012

Origin

Activity

Non-specified

Two endolysins, described by Schuch et al. (2002) and Yoong et al. (2006) (Table 4),
were studied in vivo in murine models with promising results against B. cereus, which was
used as a model for B. anthracis. Endolysin PlyG activity was effective in mice infected with
10^ CPU B. cereus RSVFl cells, resulting in a 76.9% survival rate in five hours (Schuch et

al., 2002). In addition, a dose of PlyG enzyme was injected alone in mice without any toxic
effect. Lysin PlyPH was also effective in infected mice with 2.5x10^ CPU B. cereus RSFVl
strain. All control mice died after 38 hours, whereas 40% of treated mice survived (Yoong et
al., 2006). Similarly to lysin PlyG, no toxicity was detected in mice where only the enzyme
PlyPH was injected.
A number of newly studied enzymes from Bacillus phages are described in Table 4.
Lysin PlyBt33 was active against a broad range of bacteria; B. suhtilis, B. cereus, B.
anthracis, B. tliuringiensis, Pseudomonas aeruginosa, Yersinia pseudotuherculosis and
Escherichia coli (Yuan et al., 2012). The Aly-chemotype of peptidoglycan from B. species is
a common feature shared by Gram-negative bacteria, which can be considered as the target
for these lytic enzymes. A number of other pathogenic bacteria also share this peptidoglycan
structure, such as Mycobacteria and others that have not yet been tested (Catalao et al., 2011).
The B. cereus lysin LysB4 was demonstrated to have a broad spectrum of activity including
B. cereus, B. suhtilis and L. monocytogenes. However, in the presence of EDTA, it also
successfully eliminated E. coli, E. coli 0157:H7, P. aeruginosa, C. sakazakii, S. enteritidis, S.
flexmeri and S. hoydii (Son et al., 2012). LysBPS13 is not inactivated at 100°C, which has
effects in foods which have been subjected to high temperature treatments during processing
(Park et al., 2012).
2.5. En terococcus faecal is
Enterococcus faecalis belongs to the normal human flora of intestinal tract and is
ubiquitous in nature. E. faecalis was reported to be involved in many opportunistic infections
such as urinary tract infections, bacteraemia, sepsis in newborns, peritonitis and endocarditis
(Fisher et al., 2009; Poh et al., 2006; Emori et al., 1993). This bacterium is also involved in
nosocomial infections in healthcare surroundings due to their resistance against antibiotics,
especially vancomycin (Lee et al., 2013). Endolysins from E. faecalis phages are described in
the following table.
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Table 5. Synopsis of key characteristics of cloned E. faecalis endolysins with different spectrum of
activity.
Origin

Name

Activity

Presence of cell
wall-binding
domain

Studied
in VIVO

„ „
Kelerence

E. faecalis 01

PlyV12

amidase

+

Yoong et al., 2004

E. faecalis OEFAP-1

FFAL-1

amidase

+

Son et al., 2010

E. faecalis (i^EFlAC

ORF9

amidase

-

Uchiyama et al., 2011

E. faecalis OF 170/08

LyslVO

amidase

-1-

Proenca et al., 2012

E. faecalis OF 168/08

Lysl68

endopeptidase

+

Proenca et al., 2012

E. faecalis phages endolysins were characterised very recently and as such, none of
these enzymes have been tested in vivo to date. These five endolysins were, however, tested
in vitro to determine their spectrum of activity. Lysin PlyV12 is active against E. faecalis but
also against vancomycin-resistant enterococci, staphylococci. Group A, B and C streptococci
(Yoong et al., 2004). This was the first lytic enzyme that demonstrated lytic activity within
such a broad range. Similarly, Son et al. (2010) studied the lytic potential of lysin EFAL-1
against different bacteria. A lOpg dose of EFAL-1 enzyme killed E. faecalis, E. faecium, S.
agalactiae and S. nheris. The ability for these enzymes to be effective against different genus
suggests that lysins PlyV12 and EFAL-1 target a common structural feature shared between
these bacteria. Lysins ORF9, LyslTO and Lysl68 demonstrated a narrow spectrum of
activity. Indeed, Uchiyama and colleagues (2011) reported that ORF9 lysin is effective
against 97% of E. faecalis strains and 60% of E. faecium, but no activity was detected against
staphylococci and E. coli. Lysins Lysl70 and Lysl68 were characterised and tested by
Proenca et al. (2012). Both endolysins had a different catalytic domain, thus different levels
of lytic activity. 5pg of lysin Lysl70 was able to kill 97% of E. faecalis and 54% of E.
faecium isolates. The same quantity of lysin Lysl68 was active against 81% of E. faecalis
and 42% of E. faecium isolates. Lysins Lysl70 and PlyV12 have a catalytic domain at their
N-terminal domain, comprised of an N-acetylmuramoyl-L-alanine amidase and demonstrated
different spectra of activity (Proenca et al., 2012).
Phage endolysins from the same genus were demonstrated to have different lytic
potential. This highlights different degrees of hypothetical involvement of the cell wall
binding domain in the lytic process.
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2.6. Clostridium species.
Clostridia are anaerobic bacilli, many of which are highly pathogenic to humans and
animals. They are naturally found in soil, marine sediment and human intestines (Yang et ah,
2013). Different Clostridium species are involved in human or animal diseases. C.
perfringens is responsible for gas gangrene, necrotic enteritis in humans and animals, and
also produces an enterotoxin involved in food poisoning (Sparks et ah, 2001). C.
turohutyricum and C. sporogenes are mainly involved in food spoilage, especially in cheese,
where their gas production results in cheese blowing in hard and semi-hard cheeses (Ingham
et ah, 1998; Klijn et ah, 1995). C. difficile is responsible for hospital-acquired infections and
its exotoxins, A and B, are responsible of pseudomembranous colitis (Elliott et ah, 2007). A
number of endolysins against these species are described in Table 6.
Table 6. Synopsis of key characteristics of cloned Clostridium phage endolysins.

Name

Activity

Presence of
cell wall
binding
domain

Number of
binding
domains

Target

perfringens
U).1626

Fly3626

amidase

Nonspecitled

Nonspec i lied

C.
perfringens

Zimmer et al.,
2002

C. difficile OCD27

CI)27L

amidase

+

I

C. difficile

Mayer et al..
2008

C. tiirobiitxricuni
OCTPI

Clpll

glycosidase

Nonspec i fled

C.
turohutyricum

Mayer et al.,
2010

C. perfringens
OSMiOl

psm

muramidase

-1-

2

C.
perfringens

Nariya et al.,
2011

C. sporogenes
(I)ATCC 8074-Bl

CS74L

amidase

-

-

C. sporogenes

Mayer et al.,
2012

Origin

Studied
in VIVO

„ ..
Keterence

Similarly to endolysins associated with the genus Enterococcus, Clostridium phage
lytic enzymes

are less well characterised compared to those of streptococci and

staphylococci; as such, none have been tested in vivo to date. The studies carried out by the
different authors demonstrated that each of these endolysins have a narrow spectrum of
activity where only the host bacterium of the phage (or close relatives) is sensitive to their
lytic effect (Mayer et ah, 2012; Nariya et ah, 2011; Mayer et ah, 2010; Mayer et ah, 2008;
Zimmer et ah, 2002). Lysin CD27L displayed a lytic activity specific to different C. dijficile
strains within a broad pH range (pH 4.5-8.3) without toxicity toward human gut commensal
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Clostridiwn-Wkt microflora (Mayer et al., 2008). Lysin Ply3626 demonstrated lytic activity
against C. perfringens, which is mainly involved in food contamination (Zimmer et al.,
2002). Lysin Psm was effective against just five C. perfringens strains (Nariya et al., 2011).
Lysin CS74L proved to have lytic activity against C. sporogenes, as lOpg of this enzyme
successfully eliminated this bacterium (Mayer et al., 2012). Finally, lysin ctpll was shown to
be effective against C. turobutyricwn (Mayer et al., 2010). To date, lysin CD27L is the only
reported lytic enzyme effective in a broad range of pH against C. difficile. Given that C.
difficile targets the intestine, an interesting application of the lysin has been reported by
Mayer et al. (2008). These workers succeeded in cloning the endolysin gene into a secretion
vector in the food-grade bacterium Lactococcus lactis to facilitate delivery of the anti-C.
difficile endolysin to the intestine.
2.7. Mycobacteria
Mycobacteria are important pathogens of humans and animals (Wilson, 2013; Sohal
et al., 2010; Chacon et al., 2004). However, significant species such as M. tuberculosis, M.
avium paratubercidosis, and M. lepsis are extremely slow-growing and thus difficult to
employ for endolysin studies. Consequently, a non-pathogenic, fast-growing species, namely
M. sniegniatis, has been used in the endolysin work. In silica studies of mycobacteriophage
endolysins revealed common features among them: a C-terminal cell wall-binding domain, a
central domain with motifs associated to peptidoglycan hydrolysis and a variety of peptidases
in the N-terminal domain. Six different peptidases at the N-terminal domain, five different
amidases and glycosidases, as well as four different cell wall binding domains were counted,
which results in 120 different possible combinations for potential anti-mycobacterial
endolysins (Payne et al., 2012). Recent studies established the full functioning of the
mycobacteriophage Ms6 endolysin lytic cassette against M. sniegniatis (Catalao et al., 2011a,
201 lb, 201 Ic, 2010). Peptidoglycan hydrolases were shown to be specific towards particular
peptidoglycan crosslinking types. Mycobacteria have a Aly-chemotype

peptidoglycan

composed of peptide bridges (L-Ala, D-Glu, D-Ala, meso-diaminopimelate or m-DAP)
linked by interpeptide bridges (4^3 D-Ala, m-DAP and 3^3 m-DAP, m-DAP) involved in
M. tuberculosis pathogenicity (Payne et al., 2012) (Fig. 2). The complex nature of Alychemotype peptidoglycan of mycobacteria explains the difficulty for antibacterial agents to
be effective in this case. Muramic acid residues are N-glycosylated and involve a resistance
to lysozyme, residues D-Glu and m-DAP in peptide bridges may be amidated and the
peptidoglycan is heavily cross-linked.
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Figure 2. Representation of mycobacterial Aly-type peptidoglycan with different activities identified
from mycobacteriophage endolysins (Payne et al., 2012). 1: N-acetyl-P-D-muramidase, 2: N-acetyl-PD glucosaminidase, 3: N-acetylmuramoyl-i-alanine amidase, 4: L-alanoyl-D-glutamate
endopeptidase, 5; y-D-glutamyl-meso-diaminopimelic acid peptidase, 6: D-Ala-m-DAP
endopeptidase, 7: m-DAP-m-DAP endopeptidase.

The gene gpJ encodes for a chaperone-like protein that is reported to be responsible
for the interaction with 60 amino acids at the N-terminal domain of lysin LysA, which will
then allow delivery of the enzyme to the peptidoglycan of host cell in a holin-independent
manner (Catalao et al., 201 la). The gene gp2, encoding for lysin LysA, generates two gene
products of different sizes: 27kDa, Lys24i, and 43kDa, Lys384, suggesting that M. smegmatis
infection by Ms6 phage is the result of two translational occurrences. Both forms have a
peptidoglycan hydrolase-like activity and are necessary to achieve total lysis of M.
smegmatis, but Lys384 is the only enzyme that interacts with Gpl (Catalao et al., 2011b).
Protein LysB, encoded by the gene gp3, is an enzyme with demonstrated lipolytic activity
involved in the hydrolysis of ester bonds between mycolic acids and arabinogalactan from the
peptidoglycan complex, destabilising the outer-membrane of mycobacteria. Gene gp4
produces a protein with a transmembrane domain (TMD) and a signal-arrest release (SAR)
domain in its N-terminal domain. Gene gp5, a putative holin-like protein with a single TMD
membrane-spanning a helix at the N-terminus, forms pores in the cell membrane of host cells
(Catalao et al., 201 la). Catalao et al. (2010) demonstrated that lysin LysA and Gpl expressed
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together resulted in M. smeginatis cell lysis. Subsequent combinations with lysin LysA, Gp4
and Gp5 gave negative results and as such it has been concluded that Gp4 or Gp5 are not able
to form holes large enough in the cell membrane for the release of lysin LysA. Further crosslinking studies proved that Gp4 and Gp5 interact with each other. These results demonstrate
that Gp5 might have a control over Gp4 function during the lytic cycle and that Gp5 interacts
with LysA to effect lysis of the host cell.

gpl^^

hsA

h'sB

Figure 3. Schematic representation of the Mycobacterium smegmatis Ms6 bacteriophage lysis cassette
(Catalao et al., 2011).

2.8. Clavihacter species:
Clavihacter michigaiiensis subspecies michiganeiisis is a Gram-positive bacterium
responsible for diseases in tomato plants resulting in commercial losses in agriculture
(Strider, 1969). Endolysins from phages CMPl and CN77 are both lytic enzymes that were
successfully cloned, purified and finally tested against C. michiganeiisis strains. Both lysins
are peptidases that kill C. michiganeiisis cultures within nine minutes (Wittman et al., 2010).
Table 7. Synopsis of key characteristics of cloned Clostridium endolysins

Origin

Name

Activity

Presence of
cell wall
binding
domain

Number of
binding
domains

Studied in
vivo

Reference

C. michiganeiisis OCMPI

CMPl

peptidase

+

1

-

Wittman et al.,
2010

C. michiganensis OCN77

CN77

peptidase

+

1

-

Wittman et al.,
2010

3. Endolysins against pathogenic Gram-negative bacteria.
Recent studies have investigated the applicability of Gram-negative phage endolysins.
The use of endolysins against Gram-negative bacteria is compromised by the fact that the
outer membrane forms a physical barrier, preventing access of exogenous endolysin to the
peptidoglycan. Consequently, the majority of the endolysin research work worldwide has
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focused on Gram-positive systems. Recently, a number of Gram-negative endolysins have
become a focus of research interest; these are summarised in Table 8.
Table 8. Synopsis of key characteristies of cloned Gram-negative phage endolysins.

Origin

Name

Number
of
catalytic
domains

Activity

Presence of cell
wall-binding
domain

Studied
m VIVO

„ „
Kelerence

E. coli OT4

Lysozyme

1

Muramidase

Non-specifled

Tsugita et al.,
1968

P. aeruginosa 06

P5

1

endopeptidase

Non-specified

Caldentey et al.,
1992

E. coli OT5

lysin OT5

1

peptidase

Non-specified

Mikoulinskaia et
al., 2009

P. aeruginosa OKZ

Gpl81

2

transglycosylase,
muramidase

+

Briers et al., 2007

P. aeruginosa OEL

ELI 88

1

Transglycolase

+ (2)

Briers et al.,
2011a

P. aeruginosa OKMV

KMV45

1

Non-specilled

Non-specilled

Briers et al.,
2011b

P. chlororaphis 02()l(p2-l

2()l(p2]gp229

1

glycosidase

+

Walmagh et al..
2012

P. fluorescens OOBP

()BPgp279

1

glycosidase

+ (2)

Walmagh et al..
2012

Acinelohacter baumannii
OAB2

LysAB2

1

glycosidase

Non-specilled

Lai et al., 201 1

Klebsiella pneumoniae
OKI 1

K11gp35

1

amidase

Non-specilled

Walmagh et al.,
2012h

Klebsiella, pneumoniae
OKP32

KP32gpl5

I

amidase

Non-specilled

Walmagh et al.,
2012b

S. enterica OPsP3

PsP3gplO

1

glycosidase

Non-sped tied

Walmagh et al..
2012b

S. Typhimurium OSPNIS

Lysin
SPNIS

2

glycosidase.
muramidase

Non-specilled

Lim et al., 2012

The endolysin from the E. coli bacteriophage T4, called lysozyme, was the first
Gram-negative lytic enzyme to be studied (Tsugita et ah, 1968). It demonstrated a higher
lytic efficiency compared to the isolated egg white lysozyme and also demonstrated an ability
to eliminate B. suhtilis in potatoes (de Ahrenholtz et ah, 2000). Endolysins from phages of
the genus Pseudomonas have been characterised and it was reported that their structure is
diverse. However, as yet, these have not been subjected to in vivo studies. Lysins OBPgp279

and ELI 88 have an unusual structure, as both have two cell wall-binding domains at their Nterminus and their single catalytic domain is situated at their C-terminus. Lysin OBPgp279
k:lls P. aeruginosa PAOl and also the multi-drug resistant strain Br667, without outermembrane permeabilisation. Lysin 201(p2-lgp229 was effective only against P. aeruginosa
PAOl in the presence of EDTA, which facilitated penetration of the outer membrane by the
endolysin. Both endolysins OBPgp279 and 201(p2-lgp229 have a lysozyme-like activity.
Walmagh et al. (2012) explained their respective different lytic efficiency by their different
primary protein structure and also by the presence of a second cell wall-binding domain at the
N'-terminus in lysin OBPgp279 (Table 8). Lysin EL 188 showed activity against antibioticresistant P. aeruginosa strains Br667, Br776 and PAOL The combination of EDTA and lysin
ELI88 reduced the P. aeruginosa cell titre by 4-log units (Briers et ah, 2011). The lysin PVPSElgpl46 was shown to have a lytic activity against P. aeruginosa PAOl but also against
Salmonella Typhimurium LT2 when used in combination with EDTA (Walmagh et al.,
2012). A number of lytic enzymes have been reported to be effective when integrated within
a lysis cassette mechanism which permitted secretion from its host. One of these is the
Pseudomonas endolysin KMV45, which is released gradually, after which it showed
efficiency against EDTA-treated P. aeruginosa PAOl (Briers et al., 2011). Most Gram
negative bacterial peptidoglycans share a common Aly-chemotype structure (Walmagh et al.,
2012), and as such, the efficiency of these endolysins against Gram-positives with the same
peptidoglycan chemotype can be studied. The Gram-negative lysin LysAB2 from
Acinetobacter haunumnii has been demonstrated to have activity against a number of Grampositives and Gram-negatives (Lai et ah, 2011). The S. Typhimurium endolysin SPNIS was
also inhibitory against a wide-range of Gram-negative bacteria including E. coli, Salmonella,
Shigella, Pseudomonas, Cronohacter and Vibrio. However, it showed no efficacy against
Gram-positives (Lim et ah, 2012). This demonstrates that the enzyme targets a common
structural feature in Gram-negative bacterial peptidoglycans.

4. Endolysin engineering
Endolysin engineering is a recent application for these enzymes to change and
improve their lytic activity. Most of the work carried out in that area has focused on Gram
positive endolysins, with only one Gram-negative lytic enzyme having been modified to date
(Table 9).
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Table 9. Synopsis of engineered endolysins-derived constructs.
ConstrucKs)

Native endolysin(s)

Result

Reference

GplSl

M8

Increased activity

Briers et al., 2008

LysK

CHAPk (endopeptidase)

Increased activity

Horgan et al., 2009

(t>Twort. (I)NM3

ClyS (Twort amidase + NM3 CWBD)

/

Daniel et al., 2010

Lys 168-87 (Lysl68 CHAP -t- Lys87 CWBD)

Increased solubility

Resch et al., 2011

Lys 170-87 (Lys 170 amidase + Lys87
CWBD)

Increased solubility

Resch et al., 2011

CD27Li.i79 (amidase)

Increased activity

Mayer et al., 2011

CS74L|.|77 (amidase)

Same activity

Mayer et al., 2012

CS74Li.|77-t- CD27L|x().27() (CS74L amidase -iCD27LCWBD)

Reduced activity

Mayer et al., 2012

/.SA2-E-Lyso-SH3b (>^SA2 endopeptidase -ilysostaphin CWBD)

Reduced activity

Schmelcher et al., 2012

LSA2-E-LysK-SH3b (LSA2 endopeptidase -fLysK CWBD)

Reduced activity

Schmelcheret al., 2012

Lys87, LysI68, LysI70

CD27L

CS74L. CD27L

aSA2,

Lysostaphin. LysK

Three engineered endolysins demonstrated an increased efficiency compared to their
native enzymatic form. The P. aeruginosa endolysin Gpl81-truncated construct MS,
containing only its C-terminal catalytic domain, demonstrated a lytic activity that was 12times higher than egg white lysozyme against its host (Briers et ah, 2008). Also, the truncated
construct was successfully tested against different pre-treated Gram-negatives that the native
lysin Gpl81 cannot eliminate, including E. coli, Y. enterolitica, S. Typhimurium, P. putida
and P. fluorescens.
The chimeric lysin ClyS results from the fusion of the amidase of the S. aureus
bacteriophage Twort endolysin with the cell wall-binding domain of S. aureus cI)NM3
enzyme (Daniel et ah, 2010). Endolysin LysK has been truncated to generate CHAPk, with a
reported two-fold higher lytic activity against MRSA (Morgan et ah, 2009). Both endolysins
ClyS and CHAPk were studied in vivo and both reduced MRSA-colonised nasal cavities of
mice by 2-log within one hour of treatment (Daniel et al., 2010; Fenton et ah, 2010).
The C. difficile phage endolysin CD27L has been truncated to its amidase domain to
generate CD27Li.i79, and the resulting construct eliminated C difficile strains, C.
hifennentans, C. sordellii, B. cereus, B. subtilis, B. ainylofiquefaciens, L. monocytogenes, L.
ivanovii, L. innocua and EDTA-treated E. coli, all of which had an Aly-chemotype
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peptidoglycan (Mayer et al., 2011). Other bacteria with different peptidoglycan chemotypes,
including M. luteus, S. aureus, B. longum, P. pentosaceus, B. hifidum and Euchrysops barkeri
(with A2, A3a, A3p, A4a, A4p and B-chemotype peptidoglycan respectively), were
insensitive to the truncated and native CD27L endolysin. More recently, the C. sporogenes
endolysin CS74L was truncated at its catalytic domain (amidase domain), namely CS74Li.i77,
and this construct was subsequently fused to the cell wall-binding domain of the endolysin
CD27L, resulting in a chimeric endolysin (Figure 4) (Mayer et ah, 2012). The truncated
construct CS74Li.i77 and the native lysin CS74L had the same range of action with different
activities depending on the strain. The chimeric construct lytic activity was reduced against
C tyrohutyricum and disappeared against C difficile.
The virion-associated peptidoglycan hydrolase HydH5 has been truncated and the
resulting constructs were fused with different domains of lysostaphin (Figure 5) (RodriguezRubio et ah, 2012). The fusion of the native lysin HydH5 and the cell wall-binding domain
from lysostaphin, namely HydH5SH3b, increased lytic activity by 8-fold against S. aureus.
Similarly, the fusion of the cell wall-binding domain from lysostaphin with the truncated
CHAP domain from lysin HydH5 was reported to improve the former truncated CHAP lytic
activity by 64-fold against S. aureus.
The fusion of the lysin Lys87 cell wall-binding domain and the catalytic domain of
lysins Lysl68 (cysteine, histidine-dependent/peptidase, or CHAP) and Lysl70 (amidase),
respectively, were carried out in order to solve the solubility problem of the native Lys87
enzyme (Fig. 4) (Fernandes et ah, 2012; Cantante et ah, 2008). Poor solubility was reported
for the native protein, resulting in low yield in purification. Both chimeric constructs were
successfully purified and their activity was studied against 100 clinical MSS A and MRSA
strains. A 0.2pg-dose of lysin Lys 168-87 enzyme was active against 83% of the tested
strains, whereas the same dose of Lys 170-87 was effective against 70% of these.

(a)

(b) n

CHAP

Aniidase-2

cwbdI^

Lvsl68 87

CWBD

Lvsl70 87

Figure 4. Schematic representation of chimeric constructs comprising (a) enterococcal CHAP with the
staphylococcal cell wall-binding domain (CWBD) designated Lys 168-87; (b) the enterococcal
amidase with same CWBD designated Lys 170-87 (Fernandes et ah, 2012).
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4.1. Endolysin site-directed mutagenesis
Lysin Cpl-1 has been reported to be effective against S. pneumoniae, but with a short
half-life in plasma, which can be an issue for its application as a therapeutic agent (Resch et
ah, 2011). The C-terminal domain of lysin Cpl-1 was found to be homologous to the Cterminus of the LytA. It was also shown that the last 13 C-terminus amino acids are involved
in enzyme dimerization (Fernandez-Tornero et ah, 2001) and it has been proven that in a
number of cases, endolysins dimerise when they come into contact with peptidoglycans, and
become active (Varea et ah, 2000). Ten amino acids among these were identical to the Cterminal of lysin Cpl-1. The author introduced cysteine residues within this 10-amino-acid
region of Cpl-1 permitting the formation of a disulphide bridge, inducing more rapid lysin
dimerisation. The resulting construct demonstrated a 2-fold increase in lytic activity against
pneumococci and also a 10-fold decrease in lysin clearance from blood plasma (Resch et ah,
2011).

5. Engineered lysin secretion systems
Lactic acid bacteria are associated with many fermented food systems and several
members have been exploited as probiotics. As such, they are potential candidates for the
production and secretion of recombinant therapeutic proteins (Hanniffy et ah, 2007; Nouaille
et ah, 2003; Steidler et ah, 2000). Gaeng et ah (2000) were the first group to successfully
clone and express phage endolysins in L. lactis, where it showed activity against Listeria
monocytogenes in cheese. These workers also expressed endolysins in Lactobacillus (Turner
et ah, 2007). Mayer et ah (2008) succeeded in secreting the C. difficile endolysin CD27L in
L. lactis. Similarly, the staphylococcal endolysins LysK and LysH5 were also expressed and
secreted in L. lactis by O’Flaherty et ah (2005) and Rodrfguez-Rubio et ah (2012),
respectively. Such approaches are likely to be of significant benefit where recombinant
endolysins would be secreted by lactic acid bacteria, which might be used as therapeutic
probiotics to eliminate intestinal pathogens.
6. Conclusion.
Recent studies have highlighted the potential of endolysins to be used as a novel
treatment for bacterial infections. Endolysins demonstrated lytic activity against most
problematic pathogenic Gram-positive and Gram-negative bacteria. The use of mutagenesis
and fusion of proteins to improve their efficiency and/or bacterial specificity is very
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promising. The combinations of different endolysins with distinct lytic activities and also
with other antimicrobials are also credible solutions for the treatment of bacterial infections.
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Chapter 2

Establishment of standard operating procedures and determination of
yield for the production of the bacteriophage-derived peptidase
CHAPk
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Abstract
The gene for the bacteriophage K-derived peptidase CHAPk (Cysteine/Histidinedependent amidohydrolase peptidase) was cloned into the vector pQE60 in E. coli XL 1-Blue.
Twenty batches of two litres each of the E. coli clones containing the vector with the CHAPk
insert were grown and induced with Isopropyl (3-D-l-thiogalactopyranoside (IPTG) to
overexpress the CHAPk. This chapter outlines the standard operating procedures (SOPs) for
the production and purification of the enzyme. The yield observed among the twenty different
batches resulted in a stock with an activity of 190U nmol'* and a concentration of 7.5mg ml'*.
Optimization of these procedures was also carried out. The SOPs include parameters for the
E.

coli culture

growth,

lysis,

SDS-PAGE

and

zymogram

analysis, ion-exchange

chromatography, desalting, filtration and determination of the concentration and activity of
the protein. The various data obtained were tabulated in the results section and the yield of
the CHAPk protein production was determined using optimized conditions.
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Introduction
Characterization of recombinant endolysins requires their production, purification and
activity determination in order to facilitate the study of their lytic activity against pathogenic
bacteria. The complete process required for the study of endolysins involves the optimisation
of numerous parameters. The health and age of the cells used affect the quality and quantity
of the protein expressed. Indeed, metabolically compromised or older cells may produce less
protein.

Proteins produced in bacteria must be extracted prior to purification by

chromatography (Agerkvist and Enfors, 1990). Cell lysis is achieved by either mechanical
means or by the use of chemicals which disrupt the cells (Doebler et ah, 2009) and the
subsequent use of high-speed centrifugation is required for separation of the crude extracts
resulting from cells lysis (Hochuli, 1992). In this study we outline a purification method that
will yield the best possible quantity and quality (native structure or denatured) of protein.
Chromatography is a highly efficient way to separate proteins (Nielsen et ah, 2008). Ionexchange chromatography, used for CHAPk purification, corresponds to the competitive
binding of proteins different in charge to an oppositely charged chromatographic medium
(Hedhammer et ah, 2006). However, certain issues with production and/or purification may
arise such as inconsistency, insolubility, low yield and low activity and as such, it is usually
advisable to check for protein over-expression before purification as problems can often
occur in the expression stage (Savitsky et ah, 2010). Most proteins can be produced in greater
quantities than in their native environment but they are sometimes produced in a denatured,
inactive form that accumulates intracellularly as inclusion bodies and such protein-forms are
independent on their type (Sahdev et ah, 2008). Biological activity is dependent on whether
or not the protein has been correctly folded. Certain proteins may assemble poorly in the
cytoplasm of the producing strain and they may fold incorrectly. Frequently, the purified
sample may contain salts and other low molecular contaminants that will need to be removed
(Berg, 2002). Desalting is a simple and rapid method that will remove these contaminants
while at the same time, the proteins can be concentrated gently and fast (Ward and Swiatek,
2009). The aim of this study was to provide the yield of CHAPk production with twenty
batches of 2 litres-cultures using the various optimized parameters, including culture
propagation schedule, lysis, SDS-PAGE, zymogram analysis, ion-exchange chromatography,
desalting, filtration defining parameters for specific activity and concentration determinations
of the purified lytic enzyme.
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Materials and Methods.
Production of CHAPk.
A) Materials:
1. CHAPk clones: E. coli XLl-Blue cells (Agilent Technologies, California, USA)
containing pQE60 vector (Qiagen, Hilden, Germany) with CHAPk insert (grow
culture overnight at 37 °C in superbroth with 200 pg ml ' of ampicillin).
2. Superbroth: Dissolve 32g tryptone (Sigma Aldrich, Missouri, USA), 20g yeast extract
(Sigma Aldrich), 5g NaCl in 1 litre of distilled water. This is autoclaved at 121 °C for
15min and allowed to cool down before use.
3. Ampicillin (Sigma Aldrich): A stock of 100 mg ml ' is made up.
4. IPTG (Sigma Aldrich): Final concenctration required in superbroth for protein
induction: 1 inM. Make up a working stock of 0. IM IPTG. Aliquot 10 ml volumes
into sterile 15 ml tubes. Store at -20 °C.
5. Sodium acetate (Sigma Aldrich): 50mM sodium acetate pH 6.5 (Binding Buffer).
6. Bijou bottles (autoclaved).
7. Spectrophotometer (UV-1800, UV spectrophotometer, Shimadzu, Kyoto, Japan) and
cuvettes.
8. Shaking incubator (Forma Incubated Benchtop, Orbital Shaker, Thermo Scientific,
Massachussets, USA).
B) Method:
1. Add ampicillin stock to 1 litre of Superbroth (final antibiotic concentration: 200pg ml'

2. Add 10 ml of the overnight culture of CHAPk clones to 1 litre of Superbroth.
3. Place the culture in the shaking incubator at 37 °C with shaking at 170ipm.
4. Check frequently the OD of the culture at 590nm until it reaches an OD of 0.45.
5. Place the culture on ice for 30min.
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6. Add 10 ml of 0.1 M IPTG to the culture and put it back into the shaking incubator at
26 °C for 14 hours while shaking at 170 rpm. (Final concentration of IPTG is 1 mM).
7. Aliquot the culture into 250 ml centrifuge tubes and centrifuge at 12000 rpm for
lOminutes at 4 °C. The supernatant is discarded.
8. Re-suspended each pellet in 2 ml of binding buffer. Pool these together in 5 ml bijou
bottles. Store these at -80 °C.
Lysis of CHAPk clones.
A) Materials:
1. Frozen CHAPk clones in 5 ml bijou bottles.
2. BugBuster Protein Extraction solution (Novagen, Wisconsin, USA).
B) Method:
1. Thaw the cell paste to room temperature.
2. Mix 5 ml of cell paste with 3.5 ml of BugBuster® solution (IX Tris) into a 50 ml
centrifuge tube.
3. Mix gently for 20 min at room temperature using the Ikalabortechnic KS501 digital
roller.
4. Centrifuge the tubes at 6000 rpm at 4 °C for 20min.
5. Transfer the supernatant to a new tube and discard the pellet.
6. Centrifuge the supernatant at 6000 rpm at 4 °C for 20min.
7. Keep the supernatant in a new tube and discard the pellet. Keep the tube on ice during
the purification.
Note: 30 pi of supernatant can be analysed at this stage for protein overexpression
using SDS-PAGE.
SDS-PAGE and Zymogram.
A) Materials:
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1. 30% bisacrylamide solution (3.3% C, BioRad, California, USA).
2. Zymogram: Overnight 50ml culture of S. aureus DPC5246 in BHI. Autoclave the
culture at 121 °C for 15min. Spin the culture at 12000 rpm for lOmin and remove the
supernatant. The cell pellet can be used straight away or kept at -20 °C for future use.
3. Tris base (Sigma Aldrich)
4. 500 ml of 1.5 M Tris buffer pH 8.8. This is autoclaved and stored at 4 °C.
5. 500 ml of 0.5 M Tris pH 6.8. This is autoclaved and stored at 4 °C.
6. (10% w/v) SDS: Ig SDS is dissolved in 10ml sterile distilled water. This is filtered
stored at room temperature.
7. Ammonium persulphate (APS) (Sigma Aldrich): (10% w/v required). Weigh 0.02g in
a 2ml eppendorf, make up to 0.2g with distilled water (make up same day as making
the gel).
8. 5X Electrode buffer stock solution: 9g Tris base (Sigma Aldrich), 3g SDS and 43.2g
of glycine are dissolved in 550ml of distilled water. This is stored at 4°C.
9.

IX Electrode buffer solution: 100ml of 5X electrode buffer stock solution is added to
400 ml of distilled water.

10. Staining solution: 0.5g brilliant blue, 250 ml of isopropanol and 100 ml of acetic acid
are added together and made up to 1 litre with distilled water. This is stored at room
temperature.
11. Destaining solution: 400 ml of 100% ETOH, 70 ml of acetic acid and 530 ml of
distilled water are added together. This is stored @room temperature.
12. Zymogram: Renaturation buffer: 25 mM Tris-HCl pH8 buffer with a final
concentration of 1% Triton X-100. (Dissolve lOmls of Triton X-100 in 990 ml 25m M
Tris-HCl pH8).
13. (3-mercaptoethanol (Sigma Aldrich).
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14. Stock sample buffer (SDS reducing buffer): 3.55 ml of distilled water was mixed with
1.25 ml of 0.5 M Tris base (Sigma Aldrich), 2.5 ml of 100% glycerol, 2 ml of 10%
w/v SDS and 0.2 ml of 0.5% w/v bromophenol blue.
15. Working sample buffer: 950 pi stock sample buffer is mixed with 50 pi pmercaptoethanol.
16. 55 pi of N,N,N',N'-tetramethylethylenediamine (TEMED, BioRad).
Note: Materials and gels are prepared in the fume hood
B) Methods:

Banaiu Plugs
Anod« banafw plug____________
(red)

Cathode banana plug
(black)

Notch
on U-Shaped Gasket

Inner
V Chamber
Assembly

Pressure Plate

Cams

Mini Tank

Figure 1. Mini-PROTEAN 3 cells apparatus.
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1. If samples are frozen, defrost on ice.
2. Casting frame set up:
a. Place the casting frame upright with the pressure cams in the open position
and facing forward on a flat surface.
b. Select a spacer plate and place a short plate on top of it.
c. Slide the two glass plates into the casting frame, keeping the short plate facing
outwards.

Place a Short Plate on top of tf>e
Spacer Plate.

Slide the two plates into the Casting
Frame keeping the Short Plate facing front.

Lock the pressure cams to secure
the glass plates.

Secure the Casting Frame in the Casting
Stand by engaging the spring loaded lever.

Figure 2. Assembling the Mini-PROTEAN 3 casting stand and frame.

d. Lock the casting frame in place in the holding frame.
e.

Repeat steps 2-5 for a second gel.

f.

Place a comb completely into the assembled gel cassette. Mark the glass plate
1 cm below the comb teeth. This is the level to which the resolving gel is
poured. Remove the comb.
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g. Fill the space between the plates 1/4 way up with distilled water to check for
leaks. If leaks are observed, empty out the water and dry up excess water with
tissue paper.
3. Gel preparation:
a. Make up 10% APS.
b.

Prepare the resolving gel monomer solution in small beakers as follows: 3.4
ml of distilled water is added to 4 ml of 30% bisacrylamide and 2.5 ml of 1.5
M Tris-HCl, pH 8.8 + 0.1 ml of filter-sterilised 10% W/V SDS (fume hood).

c. Zymogram: mix the resolving gel with the pellet of 50ml autoclaved cells. Add
70pl of 10% APS (freshly made) and 20pl of TEMED. Mix well with dropper
and swirl well to initiate polymerization.
d. Immediately prior to adding the resolving gel to the slides, add 50 pi of 10%
APS and 25 pi of TEMED. Mix well and swirl to initiate polymerisation.
e.

Pour to the mark using a Pasteur pipette. Pour the solution smoothly to prevent
it from mixing with air.

f.

Immediately overlay the solution with water.

g. Allow the gel to set (usually takes 15-20 min). Check any remaining gel left
in glass beaker to see if the gel has solidified.
h. Prepare the stacking gel solution: 5.1 ml of distilled water, 2.3 ml of 30%
bisacrylamide, 2.5 ml of 0.5 M Tris-HCl pH 6.8 and 0.1 ml of 10% SDS.
i.

Immediately prior to adding the stacking gel to the slides, add 50 pi of 10%
APS and 30 pi of TEMED. Mix well and swirl to initiate polymerization.

j.

Mix well with a Pasteur pipette.

k. Pipette the gel between the glass plates. Continue until the top of the short
plate is reached.
l.

Insert the desired comb between the spacers starting at the top of the plate,
making sure that the tabs at the ends of each comb are guided between the
spacers. It is easier to insert the combs starting at an angle and insert well 1
first, then 2, 3 and so on until the combs are completely inserted. Seat the
comb in the gel cassette by aligning the comb ridge with the top of the short
plate.

m. Allow the stacking gel to polymerize for 20 min.
4. Sample preparation:
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a. Add 20 [a1 of working sample buffer to 30 pi of the sample to be analysed.
b. Boil the samples for 4 min, place samples back on ice.
5. Electrophoresis module assembly:

Remove the G^l Cassette Sandwich
from the Casting Frame.

frame.

Place Gel Cassette Sandwich into tiie Electrode
Assembly with the Short Plate facing inward.

Press down on the Electrode Assembly
while closing the two cam levers of the
Clamping Frame.

Lower the Inner Chamber into the Mini Tank.

Figure 3. Final assembly of the Mini-PROTEAN 3 unit.

a. Remove the gel cassette assemblies from the casting stand.
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b. Place a gel cassette sandwich into the slots at the bottom of each side of the
eleetrode assembly. Be sure the short plate of the gel cassette faces inward.
c. Lower the Inner Chamber Assembly into the Mini Tank. Fill the inner
chamber to top with IX running buffer.
d. Leave buffer overflow into the electrode assembly until it has reached the
indicated height. If no indications are marked then add -200 ml of running
buffer to the Mini Tank (lower buffer chamber).
e. Carefully remove the combs from the gels.
6. Sample loading and gel electrophoresis:
a. Load the samples (15 pi) and the marker (8 pi) into the wells.
b. Any leftover sample can be frozen for future use.
c. Attach the SDS apparatus to the powerpack and run gel at 200V for 40-50 min
(or lower voltage for longer time.)
d. Cheek for bubbles.
e. When finished, check gel has run properly.
f. Turn off the power supply and disconnect the electrical leads.
g. Remove the tank lid and carefully lift out the Inner Chamber Assembly.
h. Pour off and discard the running buffer.
7. Staining the gels:
a. Separate the glass slides and place the gels in staining solution, shaking for at
least one hour. The green, wedge shaped, plastic gel releaser may be used to
help pry the glass plates apart. Run the sharp edge of the gel releaser along
each spacer to separate the gel from the spaeer. Remove the gel by floating it
off the glass plate by inverting the gel and plate under agitating gently until the
gel separates from the plate.
h. Zymogram: Place the gel into renaturation buffer shaking at 37°C.

c. Rinse the gels with water and place stirring in detaining solution for at least
one hour.
8. View the SDS gels under white light.
9. Rinse the Mini-PROTEAN 3 cell electrode assembly. Clamping Frame and Mini
Tank with distilled/deionized water after use.
Reference: Mini-PROTEAN 3 Cell, Instruction Manual, cat no: 165-3301 (Biorad).
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Purification of CHAPk by ion-exchange chromatography with kKTPiprime system.
A) Materials:
3. 50 mM sodium acetate pH 6.5 (Binding Buffer).
4. 50 mM sodium acetate pH 6.5 with 1 M NaCl (Elution Buffer).
5. 20%ETOH.
6. 200 mM sodium acetate in 20% ETOH (Column Storage buffer).
B) Method:

Figure 4. AYJT\prime system components.

1. Turn on computer and open the PrimeView 5.0 application.
2. Turn on the AKTA/;r//7?c system and allow to calibrate (automatic).
3. Check if the waste bottle needs to be emptied.
4. Load test tubes into fraction collector.
5. Adjust the delivery arm:
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a.

Lower the arm and allow it to move so that the tube sensor touches the test
tubes.

b.

Adjust the arm so that the sensor is about 5mm below the top of the tubes. The
tubes should always be below the horizontal mark on the tube sensor.

c.

Rotate the rack counter clockwise by hand until the rear half of the tube sensor
rests against tube 1.

6. With clean deionised water do a system wash:
a.

Put inlet tubings A1 and B in the deionised water

b.

Go to templates - press ok

c.

Go to application templates - press ok

d.

Go to system wash - press ok

e.

On the screen it should say: 'A,B,_,_, ok'

f.

Underline 'ok' - press ok

g.

Press ok to start run.

7. Do a “system wash” a second time.
8. Press escape.
9. Place the two inlet tubes A1 and B in binding buffer.
10. Go do a “manual run”:
a.

Go to “Templates” - press ok

b.

Go to “Application Template” - press ok

c.

Press down until reaching “Manual run” - press ok.

d.

Press down until reaching “Set Flow Rate” - press ok.

e.

Using up arrow set flow rate at 1 ml min' - press ok.

f.

Press up arrow until screen says “Press OK to start run” - press ok.
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11. When il has been running for approximately 5minutes, take column wire off.
12. Unscrew the top of a “Capto-S 1 ml Column”.
If this is the first time the column is used, remove the snap-off end at the end of column.
Also for first time use of the column (or for long term storage), the column should be
washed as follows:
1.

Wash the columnwith 5 column volumes of binding buffer.

2. Wash the columnwith 5 column volumes of elution buffer.
3. Wash the columnwith 5 column volumes of binding buffer.
13. Let the fiow from the column wire drop into the column in a drop to drop way to
avoid air bubbles.
14. Carefully screw the column wire onto the column. The drops should be seen coming
out of the end of the column.
15. Screw the end of the column into the machine, taking care with the column wire.
16. Let the run continue for another 15min.
17. Monitor that the How through goes into the waste bottle.
18. End the “Manual run”.
19. Load the syringe with 5 ml of binding buffer and attach it to the “Injection valve”.
20. In the “Manual Run” menu, set the injection valve to position “LOAD” and carefully
inject the sample into the sample loop. Do NOT remove the syringe after the
injection. Otherwise, the loop might be emptied due to self-drainage.
21. The sample will be injected onto the column when the valve is switched to “INJECT”
in the method. Take off the syringe and repeat steps 19, 20 and 21 three times.
22. In a sterile universal, mix 3 ml lysed cells supernatant (unpure CHAPk) and 2 ml
binding buffer and load the syringe with the mix. Attach the syringe to the “Injection
valve”
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23. In the “Manual Run” menu, set the “Injection valve” to position “LOAD” and inject
carefully the 5ml mix into the sample loop. Do NOT remove the syringe after the
injection.
24. Set the “Injection valve” to position “INJECT” and leave the syringe on the “Injection
valve”
25. Put inlet tube A1 in binding buffer and put inlet tube B in elution buffer and press
“Escape”.
26. Press down until reaching “Stored Program Method” - press ok.
27. Underline “System” - press ok.
28. Press up until reaching program number 25 - press ok.
29. Press “Run”.
Note: Typically, a purification run takes about 45 min.
30. Analyse the real time graph produced by the “PrimeView” software to identify
fractions containing CHAPk (usually fractions 6-8 and peak size is typically
between 100 and 400 mAu).
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Figure 5. Purification curve on AKTAprime automated purification system using ion-exchange
chromatography. (A) crude cell lysate peak, (B) purified protein peak.

31. Press OK at the Method Complete prompt to finish the run.
32. Transfer fractions of pure CHAPk into a sterile 2ml eppendorf, store at -20 °C.
For washing between runs:
33. Rinse the sample loop by injecting 25 ml of deionized water (5 injections with syringe
filled up with 5ml of deionized water) through the fill port on the “Injection valve”.
34. Put all used inlet tubings in deionised water.
35. In the “Templates” menu, select “Application Template” and then “System Wash
Method”.
36. Select the used inlet ports. Inlets A1 and B will always be washed.
37. Press “OK” to start the method. The system flow path is automatically flushed.
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For overnight/long term storage:
38. Wash all tubings and flow paths used with binding buffer by running the “System
Wash Method” with all tubings in binding buffer.
39. Carefully, take off the “Capto-S 1ml column” from the “Injection valve” and put back
the caps at both ends of the column.
40. Wash all tubings and flow paths used with deionised water by running the “System
Wash Method” with all tubings in deionised water.
41. Finally, wash the system with 20% ethanol and store it in 20% ethanol.
Note: For troubleshooting,

AKTAprime manual.

Desalting CHAPk
A) Materials:
1. Purified CHAPk2. Amicon Ultra-15 filter tubes (10,000 MWCO, Millipore, Massachussets, USA).
3. 25 mM Tris pH 7.0: 3.03g of Tris base (Sigma Aldrich) is dissolved in 900 ml of
distilled water. 1 M NaOH and 1 M HCl are used to adjust the pH. The Tris is then
made up to 1 litre with distilled water.
4. Swinging bucket rotor (C412, JOUAN).
B) Method:
1. Fill filter unit of the amicon tube to 14 ml with 25 mM Tris pH 7.
2. Centrifuge at 4000 rpm for 20minutes on a swinging bucket rotor.
3. Discard buffer from the tube and pipette it out of the filter unit.
4. Place 14ml of purified CHAPk into the filter unit of the Amicon filter tube.
5. Centrifuge at 4000 rpm for 20 min, discard the flow through.
6. Repeat steps 4 - 5 for the rest of the batches (i.e. batches 2 to 10 in Tube 1 and
batches 12 to 20 in Tube 2).
7. Fill up filter tube to 14 ml with 25 mM Tris pH 7.
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8. Centrifuge at 4000 ipm for 25 min.
9. Discard the How through, transfer the CHAPk from the filter unit into a sterile
eppendorf. Store at -80 °C.

Determination of CHAPk concentration
A) Materials:
1. Pierce BCA Protein Assay Kit (Thermo Scientific).
2. Microtitre plate.
3. Purified and/or desalted CHAPk protein.
4. Plate reader (SpectraMax 340, Molecular Devices).
5. 25 mM Tris pH 7.

B) Method:
1. Preparation of Diluted Albumin Standards (required in triplicate for each standard):
Use table as a guide to prepare a set of protein standards.
a.

Dilute the contents of one AlbumineStandard (BSA) ampule into several clean
vials, preferably using the same diluents as the sample(s) (use 25mM Tris).

b.

Each 1ml ampule of 2 mg ml ' Albumin Standard is sufficient to prepare a set
of diluted standards for either working range suggested in the table.

There will be sufficient volume for three replications of each diluted standard.
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Table 2. Preparation of BSA standards.

Volume of Diluent

Volume and source of

Final BSA Concentration

(pl)

BSA (pl)

(pg niF )

A

0

300 of stock

2,000

B

125

375 of stock

1,500

C

325

325 of stock

1,000

D

175

175 of vial B dilution

750

E

325

325 of vial C dilution

500

F

325

325 of vial E dilution

250

G

325

325 of vial F dilution

125

H

400

100 of vial G dilution

25

1

400

0

0=blank

Vial

2. Preparation of the BCA Working reagent (WR):
a.

200pl of WR reagent is required for each sample in the microtitre plate procedure.
Use the following formula to determine the total volume of WR required:
i. (#standards

+

#unknowns)

x

(#replicates)

x

(volume

of

WR/sample) = total volume WR required.
ii. Example: (9 standards+ 3 unknowns) x 2 replicates x 200 pl= 4.8
ml WR required
b.

Prepare WR by mixing 50 parts of BCA Reagent A with 1 part of BCA reagent B
(ratio 50:1, Reagent A:B). For the above example, combine 50 ml of Reagent A
with 1 ml of Reagent B.

Note: When Reagent B is first added to Reagent A, turbidity is observed that quickly
disappears upon mixing to yield a clear, green WR. Prepare sufficient volume of WR based
on the number of samples to be assayed. The WR is stable for several days when stored in a
closed container at room temperature.
3. Preparation of dilutions of CHAPk (required in triplicate for each dilution):
a.

1/5 dilution: 5 pi of pure CHAPk is diluted with 20 pi of 25 mM Tris.

b.

1/10 dilution: 2.5 pi of pure CHAPk is diluted with 22.5 pi of 25 mM Tris.
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c.

1/20 dilution: 1.25 \i\ of pure CHAPk is diluted with 23.75 pi of 25 mM Tris.

4. Pipette 25pl of each standard or unknown sample replicate into a microtitre plate well
(working range = 20-2,000pg mP').
Note: If sample size is limited, 10 pi of each unknown sample and standard can be used
(sample to WR ratio = 1:20). However, the working range of the assay in this case will be
limited to 125-2000 pg ml '.
5. Add 200 pi of the WR to each well and mix plate thoroughly on a plate shaker for 30
seconds.
6. Cover plate and incubate at 37 °C for 30 min.
7. Cool plate to room temperature.
8. Measure the absorbance at 562 nm in a microtitre plate reader.
9. Subtract the average 562 nm absorbance measurement of the blank standard replicates
from the 562 nm measurements of all other individual standard and unknown sample
replicates.
10. Prepare a standard curve by plotting the average Blank-corrected 562 nm
measurement for each BSA standard vs. its concentration in pg mf'. Use the standard
curve to determine the protein concentration of each unknown CHAPk sample.

Note: a. If using curve-fitting algorithms associated with a microtitre plate reader, a fourparameter (quadratic) or best-fit curve will provide more accurate results than a purely linear
fit. If plotting results by hand, a point-to-point curve is preferable to a linear fit to the
standard points.
b. For troubleshooting, refer to the manual.

Quantification of lysin activity (Daniel et al., 2010; Horgan et al., 2009; Obeso et al., 2008;
Rashel et al., 2007; Cheng et al., 2005; Nelson et al., 2001):

A) Materials:
1. S. aureus strain DPC5246.
2. BHI broth (Sigma Aldrich).
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3. 25 mM Tris buffer pH 7.
4. Desalted CHAPk of known concentration.

B) Method:
1. Grow S. aureus strain DPC5246 at 37 °C in the shaking incubator to an OD590 of 0.3
in BHI broth. Usually, a 500 ml volume of culture, upon reaching the OD of 0.3 at
590 nm, is aliquoted into 50 ml plastic centrifuge tubes.
2. Centrifuge the 50 ml tubes at 4000 g for 10 min at 4 °C (Thermo Scientific CL30R
centrifuge). Remove the supernatant. Cell pellets can be used immediately or stored at
-20 °C until required.
3. When required, resuspend one 50 ml pellet of S. aureus DPC5246 cells in 1 ml of 25
mM Tris buffer pH 7. Check the OD590 in the spectrophotometer (Shimadzu UV1800) and adjust the sample accordingly with buffer until an OD of 1.9 at 590nm is
achieved.
4. Add 100 pi of the prepared bacterial suspension to wells in a 96-well micotitre-plate.
Minimum well usage is 3 control wells (cells in buffer alone) and 3 test wells (cells in
buffer

4-

enzyme)

5. Add 100 pi of 25 mM Tris buffer pH 7 to each control well containing 100 pi of cell
suspension. Add lOOpl of purified lysin* in 25 mM Tris buffer pH 7 to the test wells
Each different lysin concentration is performed in triplicate.
^serial 2-fold dilutions of lysin from a lOOpg ml ' working stock e.g. typically for CHAPk, the
concentration of lysin in wells will range from 5 - 0.5 pg ml '.

6. Monitor decrease in OD at 590 nm at 37 °C for 15 min in the microtitre plate reader
(Molecular Devices, Spectra Max 340). Typically, the OD590 in control wells gives an
absorbance value of 0.6 nm at time 0 min.
7. At the 15 min end-point, the lowest concentration/amount of lysin that reduces the
0D59() by 50 % compared to the control wells (using average values ± standard
deviation) is defined as one unit (U) of activity. In the case of CHAPk, 5-15 pg ml"'
(l-3pg of enzyme per 200 pi well) typically corresponds to lU of activity.
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Specific Activity (S.A.) of lysin:

S.A. corresponds to the amount of enzyme activity in each mg of protein (units/mg):

S.A.=

units {enzyme activity)
mg total protein (total amount of protein in 200pl well)

e.g. If Jpg ofCHAPK {Batch X) gives one unit of activity (lOOpl of enzyme is used):

S.A.=

O.OOlmg/ml X 0.1ml

0.0001

= W,000U/mg

S.A of CHAPk (Batch X) is 1000 U mg '.

•

Specific Activity expressed as U nmol'.

For example;
a. One mg of CHAPk (Molecular weight

=

1S586.6 g mol ) contains how many

nmol?
•

CHAPk = 18586.6 g= 1 mol
=> 1

X

10'^ g = ? mol

=> 1 X lO '^g = 0.0000000538 mol
Img = 53.8 nmol
h.

S.A. of CHAPk{ 1000 U mg^) expressed as U nmol'‘:
•

CHAPk contains 10,000 units in Img of protein.

•

1 mg of protein corresponds to 53.8 nmol.
10,000 U mg' O 10,000 U/53.8 nmol

If ]000 U are contained in 53 nmol of enzyme, how many U are in I nmol of
enzyme (U nmol'')?
10,000 U/53.8 nmol = 189U nmol''
S.A. of CHAPk (Batch X) is 189U nmol ^
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Figure 6. Summary of the CHAPk production procedures.

E. co/z XL 1-Bhie cukure is grown up to OD«)o of 0.45-0.5

E. co/z cuhure induced with IPTG at26°C for 14 hours

E. coli cells har\*ested
and resulting pellet re-suspended in 2ml of binding buffer

Induced E. coH cells in bijou bottles arehsed
with BugBusterS Protein Extraction Reagent

Lysed cells are centrifuged pellet is discarded

Purification of released proteins
by ion-exchange chromatography with AKTAprime system

Purified protein fi^actions are pooled in groups of 14 maximum

Pooled fi'actions are desalted
using .Amicon LJltra-15ml centrifugal filter tubes
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Figure 7. Summary of CHAPk characterization steps.

SDS-PAGE on resulting desalted protein fractions

Fiher-steriKzation of protein stock

Determination of desalted protein fractions concentration
using BCA protein assay kit

Determination of acthity of protein stock

Results

The methods described above have been optimized and twenty batches of CHAPk
were prepared using these techniques. Each batch contained 2 litres of E. coU XL!-Blue cells
that contained the pQE60 vector. These were grown in superbroth supplemented with
ampicillin. Cultures were induced with IPTG to produce CHAPk protein at mid-log phase.
Cells were harvested by centrifugation and each pellet was resuspended in 2 ml of 50 mM
sodium acetate pH 6.5. The pellets were lysed by disruption of the bacterial cell wall using
Novagen Bugbuster® solution and the cellular debris was removed by centrifugation. The
resulting supernatant was purified using cation-exchange chromatography. The purified
protein was eluted into different fraction tubes and these fractions were later pooled together
for desalting. Fractions from ten-2 litres batches containing purified protein were pooled into
Amicon-Ultra centrifugal tubes and concentrated in 25 mM Tris pH 7. As seen in Tables 2a
and 2b, the typical length of time for the E. coli XL 1-Blue cells to reach an OD590 was around
4 and 5 hours. It has been demonstrated that the age of a culture determines the rate of growth
(data not shown). Indeed, it took approximately 6 hours to reach an OD of 0.45 at 590 nm.
The resulting supernatant from cell lysis was purified on the same day that th^' E. coli XLlBlue cells were harvested and lysed in order to get the maximum yield as possible, as it has
been previously shown that a delay in purification resulted in a loss of protein probably due
to the subsequent freezing and thawing steps. On average, 6 -7 purification runs were carried
out on each 2 litres batch and a number of these gave no purified proteins. Further
centrifugation reduced the volume of enzyme and a higher concentration of protein resulted.
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The purified fractions from ten batches were desalted in the same tube in order to get the
highest concentration possible.
Table 2a. Results summary for culture batches 1 to 10. All the fractions resulting from the purification
of the batches 1 to 10 were desalted in the same tube (Filter Tube number 1).

Batch
Bomber

Origiaal
culture vol.
(litres)

Time to
reach mid log
phase(hours)

Number of
purification
ruQs

Average peak
size
(mAu)

Fractions
containing
purified
CHAPk

1

2

4

6

467

6

Fractious
pooled for
desalting
(ml)

Filter tube
number

12
2

2

3.5

6

363

6

3

2

3.5

6

293

6

4

2

45

6

307

6

5

2

4

7

350

7

6

2

4.25

7

277

7

3.75

6

247

6

12

14

7

1

12
8

T

5

6

127

6

9

2

4

6

15

6
12

10

2

4.25

6

133

6
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Table 2b. Results summary for culture batches 11 to 20. All the fractions resulting from the
purification of the batches 11 to 20 were desalted in the same tube (Filter Tube number 2).

Batch
Bomber

Original
rnhnre vol.
(litres)

Time to
reach mid log
phase (hoars)

Number of
purification
runs

Average peak
size
(mAu)

Fractions
contaiuing
purified
CHAPk

11

2

4

6

250

6

Fractions
pooled for
desalting

Filter tube
number

(«0

13
12

2

4

7

100

7

13

2

45

6

93

6

14

2

5

6

103

6

15

2

4

6

133

6

16

2

4

6

150

6

17

2

475

6

200

6

18

2

5

6

153

6

19

2

4.5

6

100

6

20

2

4

6

107

6

12

12

2

12

12
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Table 2c. Batches characterization summary. The desalted stocks from tubes 1 and 2 were pooled
together. The resulting volume of enzyme was filter-sterilized and assessed from its concentration and
activity point of view.

Filter tube
number

^'olume of sample
after desalting
(pi)

Tubes
pooled

Volume of
stock (mi)
aner filtering

concentration
(mg/ml)

of protein
(mg)

1.6

7.5

12

Acth’itj(tVnmol)

1.000

190

900

The concentration of the desalted protein was quantified using the BCA protein assay
kit (Tables 3a and 3b). The concentrated tubes of enzyme were then pooled together to form a
unique stock of CHAPk- After the desalted CHAPk fractions were pooled together, the stock
was then filter-sterilized by passage through a 0.45 pm filter and quantified for concentration
and activity. In order to retain as much protein as possible, the filter was humidified with
buffer before sterilization and also, the concentration of the stock was determined after
sterilization to avoid waste of protein. Based on the volume and concentration of the resulting
stock, the final quantity of CHAPk protein was estimated. The 1:5 dilution results were
considered as the OD590 values had less variations between the replicates and the stock
concentration obtained was 7,500 pg ml '. A final volume of 1.6ml of stock was obtained at
the end of the experiment corresponding to a total quantity of

12

mg of CHAPk (Table 4).
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Table3a. Optical density (562nm) of standards obtained for CHAPk stock concentration from BCA
Protein Assay Kit.
Standards (OD562)
Concentration (pg ml ’)

2,000

1,500

1,000

750

500

250

125

25

0

A

2.608

2.002

1.558

1.254

1.000

0.617

0.457

0.256

0.176

B

2.731

1.993

1.734

1.232

1.038

0.668

0.469

0.312

0.243

C

2.462

2.313

1.676

1.258

1.043

0.663

0.485

0.299

0.228

Average

2.600

2.103

1.656

1.248

1.027

0.649

0.470

0.289

0.216

Minus blank

2.385

1.887

1.440

1.032

0.811

0.434

0.255

0.073

0.000

Table 3b. Optical density (562nm) obtained for each dilution of the CHAPk stock.
CHAPk concentration assay (OD562)
1 ;5 dilution

1:10 dilution

1:20 dilution

A

2.094

0.685

0.437

B

1.962

0.892

0.551

C

2.353

0.687

0.059

Average

2.136

0.755

0.349

Minus blank

1.921

0.539

0.133

Samples

Concentration (pg ml ’)

7,500

The lytic activity of the protein stock was subsequently determined using the method
previously described. Different concentrations of enzyme were used including 0.5, 1 and 2.5
|ig ml ' against S. aureus DPC5246 (Figures 8a, 8b and 8c). After 15 min, the lowest
concentration that reduced the OD at 590 nm by 50% corresponds to 1 unit of activity. As
outlined in figures 8a, 8b and 8c, the concentration of enzyme 1 pg mP' was sufficient to
reduce the OD at 590nm of S. aureus by 50%. The formulas previously described for the
enzyme activity were used and gave an activity of 190 U nmol"' for the stock (Table 2c).
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Figure 8a. Study of lytic activity of 0.5 gg ml ' of CHAPk against S. aureus DPC5246. The assay was
earned out in triplicate in a 96-well plate incubated at 37 °C for 15min. When a concentration of 0.5
pg ml ' of enzyme was used, the OD at 590nm of the culture was reduced by 0.18, which is less than
50%. Hence, this concentration does correspond to 1 unit of activity.

Figure 8b. Study of the lytic activity of 1 pg ml’ of CHAPk against S. aureus DPC5246. The assay
was carried out in triplicate using a 96-well plate incubated at 37 °C for 15min. When a concentration
of 1 pg ml ' of enzyme was used, the OD at 590nm of the culture was reduced by 0.28, which
corresponds to an OD reduction of 50% at 590nm. As a consequence, this concentration of enzyme
corresponds to 1 unit of activity.

63

Figure 8c. Study of the lytic activity of 2.5 f.ig ml ' of CHAPk against S. aureus DPC5246. The assay
was carried out in triplicate using a 96-well plate incubated at 37 °C for 15min. When a concentration
of 2.5 pg mf' of enzyme was used, the OD at 590nm of the culture was reduced by 0.18, which is
more than 50% reduction of the OD at 590nm. Hence, this concentration does not correspond to 1
unit of activity.

Discussion
Twenty batches of CHAPk were produced and from these, a stock of enzyme was
obtained from specific conditions of production and purification. The results of this study
demonstrate that CHAPk can be efficiently expressed in a biologically-active form in E. coli
XLl-Blue (pQE60) and retain its catalytic properties. However, as seen in Tables 3a and 3b,
the purification showed decreasing levels of protein with some batches only reaching 15mAu
(Absorption units) in peak size. To ensure that no CHAPk was being sent to the waste instead
of being fractionated out, it was necessary to perform an SDS-PAGE gel with samples taken
from the flow through. As these gels indicated that the enzyme was not being discarded, it
was assumed that the problem may be with the expression of the endolysin from old E. coli
cells. Therefore, for batches 11 to 20 (Table 2b), a new stock of E. coli XLl-Blue cells was
used which resulted in a steady expression of protein. For CHAPk purification, it was
necessary to first harvest the E.coli cells from each batch, resuspend the pellets in binding
buffer and then lyse the cells using Bugbuster® reagent. Resuspended pellets may have been
stored at -80°C until needed for purification, although it was found that the longer the interval
between harvesting and purifying, the less pure protein was obtained (data not shown). As a
result, E. coli XLl-Blue cells were always lysed and subsequently purified on the same day.
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Fractions from the batches were pooled into Amicon filter tubes to concentrate the protein
and remove salts which may interfere with the enzyme activity by altering its threedimensional folding. Once the filter tubes were filled to 12-14ml, they were centrifuged at
4000rpm and the flow through was discarded. Then, the fractions from 2 batches were
subsequently desalted in a same tube in order to colleet and concentrate the resulting purified
protein. Finally, the coneentrated desalted fractions were pooled together and subsequently
filter sterilised. The concentration (mg mb') and activity units (U nmol ') were determined.
An estimation of eoncentration and volume of eaeh stock was based on the desalted fractions.
The stock of protein yielded 12 mg of protein from 40 litres of E. coli XL 1-Blue
culture which gives an average of 0.3 mg of enzyme per litre. It was expected that the actual
concentration of the protein stock would be slightly lower than estimated due to the filtering
process. Indeed, by adding 25 mM Tris buffer to the stock for desalting, the coneentration of
stock trapped in the filter was slightly diluted. Previous work carried out by our group
demonstrated a better production of protein but a lower lytic activity compared to the
presented data. Indeed, it has been reported that CHAPk stock could have a lytic activity as
low as 37 U nmol''. The resulting higher activity obtained in this study may be due to the
small period between the purification and desalting steps which involves less thawing and
freezing steps whieh can alter the enzyme stability. The inlluenee of the sterilization step by
using a filter showed a loss of 300 pi of stock i.e. 16% of loss, which is equivalent to 2mg of
protein. The humidification of the filter with 25 mM Tris buffer before filter sterilization of
the protein was performed in order to reduce the losses of CHAPk as much as possible.
Previous studies on the CHAPk production always showed such loss at this stage to date and
this method was the only one found to date that reduees these. To avoid confusion for later
work, optimum methodologies defined from the various observations are the only ones
recorded in this chapter.
Endolysins have to be produced and purified in order to study their exogenous
potential applieations. The over-expression system in E. coli has been widely used as it
demonstrates interesting yields. The SOPs described in this chapter may be used as a basis for
higher-scale production of the CHAPk protein. The hypothetic establishment of a probiotic
strain secretion system, such as Lactococcus kictis or Lactobacillus, to continuously release
the endolysin for the anticipation of staphylococci infections, would be an interesting
outcome for CHAPk-
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Chapter 3

Investigation of the activity of the bacteriophage endolysin CHAPk in
blood

68

Abstract
The cysteine/histidine-dependent peptidase CHAPk, which has previously demonstrated
efficacy in vivo, was evaluated for its lytic activity against Staphylococcus aureus in blood.
Given that anticoagulants possess antibacterial activity, a range of concentrations of 70 mM
disodium hydrogen citrate and 140 mM glucose were tested to define a level that would
permit the growth of S. aureus while maintaining sufficient anticoagulant activity within
blood. The 10% concentration of anticoagulant maintained unclotted blood for two weeks
and was chosen for the experiment. S. aureus DPC5246 was challenged using a range of
concentrations of CHAPk in blood; 200 and 100 pg mP' of CHAPk were sufficient to
eliminate all bacteria within 30 minutes and one hour, respectively.
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Introduction
Staphylococci are members of the skin and mucous membrane flora in humans and
have the potential to eause a range of infections (Uhlemann et ah, 2013; Fernandes et ah,
2012; David et ah, 2010; Herold et ah, 1998). Antibiotic-resistant S. aureus, including
methicillin-resistant S. aureus (MRSA), are a major problem in hospitals and in other
healthcare settings (Klein et ah, 2013; Lindsay, 2013), hence, the necessity for the
development of alternative antibacterial strategies against pathogenic antibiotic-resistant
staphylococci. Numerous endolysins from the genus Staphylococcus have been characterised
to date and these have been previously described (Chapter 1, this thesis); a number of these
enzymes have been studied in vivo (Gu et ah, 2011; Gupta et ah, 2011; Daniel et ah, 2010;
Rashel et ah, 2007; O’Flaherty et ah, 2005). The endolysin LysK is a bacteriophage-encoded
enzyme comprised of a cysteine, histidine-dependent amidohydrolase/peptidase (CHAP)
doiPiain, an amidase domain and a cell-wall binding domain SH3b (Figure 1).

This enzyme demonstrates lytic activity against S. aureus, including MRSA and
MSSA strains (O’Flaherty et ah, 2005). The truncated derivative of LysK, containing only
the CHAP domain namely CHAPk, also showed lytic activity against MRSA (Horgan et ah,
2009). In addition, the lytic efficiency was studied in vivo in artificially infected nares of
mice and resulted in complete elimination of S. aureus cells within one hour of treatment
(Fenton et ah, 2010). CHAPk was also shown to eliminate S. aureus biofilms within 4 h and
was also effective in reducing the titres of S. aureus on skin surfaces (Fenton et ah, 2013).
These studies demonstrate that the CHAPk enzyme is a potential candidate for use as a
therapeutic agent. Nevertheless, its toxicity must be assessed in order to consider its potential
application for human clinical trials. In this study, the activity of the CHAPk protein was
assessed in artificially infected bovine blood inoculated with S. aureus to provide information
on its applicability.

Material and methods
Bacterial strains
S. aureus strain DPC5246, a bovine mastitis isolate (O’Flaherty et ah, 2005) was used
for the study and was kept at -80 °C and grown overnight in Brain Heart Infusion (BHI) broth
(Sigma, USA) at 37 °C, prior to the day of the experiment.
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Production of CHAPk
CHAPk was previously cloned in the expression vector pQE60 (Qiagen, Hilden,
Germany) in E. coli XLl-Blue. E. coli cells were grown in superbroth at 37 °C with aeration
up to an OD of 0.45 at 590 nm. Cells were induced with 10 mM IPTG and then incubated at
24 °C for 16 hours. The cells were lysed using Bugbuster® Protein Extraction Reagent
(Novagen, Billerica, Massachusetts, USA) for 15 min at room temperature. CHAPk was
purified using ion-exchange chromatography with the AKTAsystem (GE Healthcare, Little
Chalfont, UK) and desalted by centrifugation using Amicon Ultra centrifugal filters
(Millipore, Massachusetts, USA). The enzyme was stored at -80 °C in 25 mM Tris-HCl pH
7.0. The concentration of CHAPk was assessed with the Pierce® BCA Protein Assay Kit
(Thermo Scientific, Massachusetts, USA) according to the manufacturer’s protocol.
Assessment of anticoagulant concentration on survival of S. aureus
Concentrations of 70 mM disodium hydrogen citrate and 140 mM glucose were made
up by the addition of 6 g of disodium hydrogen citrate and 9 g of glucose to 360 ml of
distilled water. The solutions were filter sterilised. To investigate the ability of the
anticoagulant agent to influence the growth of S. aureus DPC5246, solutions of 5, 10 and
15% (v/v) were used with an inoculated (1%) 20 ml BHI broth from an overnight S. aureus
culture.
Kinetic effect of different concentrations of CHAPk against S. aureus in bovine blood
S. aureus was grown at 37 °C with aeration overnight in BHI broth, and a preliminary
1:10 dilution was made of the overnight culture in BHI broth. From the diluted culture, 100
pi was used to inoculate 10 ml of bovine blood. This was incubated at 37 °C overnight to
allow staphylococci to adapt to the blood environment. This was used to inoculate (10%)
fresh blood the following morning with an approximate titre of lO*’ cells per ml. Four
concentrations of CHAPk were used including 200, 100, 50 and 25 pg ml''. A 110-pl aliquot
of infected blood was mixed with 110 pi of CHAPk at either 400, 200, 100 and 50 pg ml'' in
a 96-well microtitre plate (Sarstedt, Ireland). The microtitre plate was incubated with shaking
at 37 °C for 90 min in a microtitre plate reader (Spectro Max 340, Molecular Devices). A
plate count was performed every 30 min with 100 pi of the relevant dilutions plated on BairdParker Agar (Sigma, Missouri, USA). Plates were incubated at 37 °C overnight, and each
assay was done in triplicate.
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Results
Impact of anticoagulant concentration on S. aureus DPC5246 growth in BHI broth
Anticoagulant agents in blood can have an antibacterial effect (Martini et ah, 2012;
Balestrino et ah, 2009; Shanks et ah, 2006; Weijmer et al., 2002). In order to perform CHAPk
challenge experiments against S. aureus, it is necessary that the blood be maintained in
unclotted form. Nevertheless, the concentration of anticoagulant has to be sufficiently low to
permit the survival of bacterial cells. Three different anticoagulant disodium hydrogen citrate
and glucose concentrations of 5, 10 and 15% in BHI broth were tested in the presence of S.
aureus, and a subsequent plate count on Baird-Parker agar was performed. The plate counts
are presented in Figure 2. The increase of anticoagulant concentration resulted in a slower
rate of bacterial growth as expected. At 5%^ of disodium hydrogen citrate and glucose, there
was a slight inhibition of growth resulting in a final bacterial concentration of 2.9 x 10^ CFU
mb compared to 3.8 x 10 CFU ml' for the control. In this case, the blood clotted within
three days and, thus, was unsuitable for the experiment. The addition of 10% of anticoagulant
resulted in a final titre of 1.1 x 10 CFU ml' ; in this case the blood remained uncoagulated
for two weeks and, thus, this concentration was chosen for the experiment. Use of 15%
anticoagulant resulted in slow growth with staphylococcal cell titres from 1.0 x 10^ CFU ml''
to 6.0 X 10^^ CFU mb' after seven hours.
Assessment of CHAPk activity in bovine blood against S. aureus DPC5246
CHAPk was tested at concentrations of 25, 50, 100 and 200 pg mb' to evaluate its

activity against S. aureus in blood (Fig. 3). A 25-pg mb' concentration of CHAPk did not
have any significant lytic effect on S. aureus culture as determined by the constant final plate
count average over the course of the experiment. When the concentration of CHAPk was
increased to 50 pg mb', viable cell counts were reduced by half within 30 min. When a
concentration of 100 pg mb' of CHAPk was used, the S. aureus viable cell counts were
reduced to 0 within 60 min. A concentration of 200 pg mb' of lysin eliminated
staphylococcal cells within 30 min.

Discussion
Healthcare-associated MRSA strains are responsible for 20% of bloodstream
infections in hospitals in the US (Wisplinghoff et ab, 2004), resulting in longer treatment
periods and a higher rate of mortality (Cosgrove et ab, 2005). In addition, MRSA can be
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isolated from animals and foods (Pala et al., 2004). The potential of CHAPk has been
assessed in many different studies ranging from the in vivo stage, where CHAPk eliminated
MRS A in nares of mice (Fenton et ah, 2010) and on porcine skin, to the prevention of biofilm
formation by MRSA (Fenton et ah, 2013).
This study demonstrates that CHAPk eliminates staphylococcal cells in blood within
one hour at a concentration of 100 pg ml ' (Figure 3). The observed slower activity of
CHAPk in blood compared to its activity in culture
can be explained by potential interactions of antibodies with either cells or endolysins.
CHAPk is comprised solely of the cysteine, histidine-dependent amidohydrolase/peptidase
from lysin LysK, and the resulting low molecular weight of the protein hypothetically
reduces the likeliness for a humoral immune response (Horgan et ah, 2009). When the
concentration of CHAPk was increased to 200 pg mp', it appeared to circumvent the
hypothetical antibody inhibition, and it resulted in complete elimination of S. aureus cells in
blood within 30 minutes (Figure 2). The interactions with antibodies may limit access of the
enzyme to staphylococcal cells. It was previously shown by Gu et al. (201 la) that a 50-pg
dose of lysin GH15 reduced staphylococcal litres in mice blood to undetectable levels within
two hours with the ability to reduce the levels of cytokines (Gu et al., 201 lb), suggesting that
interactions between antibodies and endolysin are minimal. The study by Gu et al. (201 lb)
reported that the injection of enzyme resulted in a reduced immune response and, as such,
this suggests that interactions occur with antibodies and staphylococcal cells only. Infection
from staphylococcal cells caused an immune response, and the resulting antibodies
hypothetically reduced access to the peptidoglycan for the endolysin, which delays the lytic
effect of the enzyme. A high concentration of enzyme would enable a faster lytic efficiency
to occur towards staphylococcal cells, which would logically result in a low immune response
where the cell’s peptidoglycan remains aecessible to endolysin. The lytic efficiency of
CHAPk has been demonstrated in blood, and the study also demonstrated possible
intravenous applications of CHAPk against MRSA for further in vivo work. Nevertheless,
blood is a matrix involved in the immune response and the injection of CHAPk may be
responsible for such a defensive response. The study of the immune response induced by the
infection by S. aureus and the following treatment with CHAPk are necessary to evaluate if
the enzyme is toxic to the host.
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Figure 1. Schematic diagram of endolysin LysK (495 residues), which contains a CHAP domain at the
N-terminus (residues 35 to 160), an amidase_2 domain (residues 197 to 346) and a SH3b cell wall
binding domain at the C-terminus (residues 481 to 495).
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Figure 2. S. aureus DPC5246 growth in Brain Heart Infusion broth with 0% (■), 5% (■), 10% (■) and
15% (■) of disodium hydrogen citrate and glucose for seven hours at 37 °C (1% inoculation).
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Figure 3. Impact of different CHAPk concentrations on S. aureus DPC5246 in bovine blood (10%
disodium hydrogen citrate and glucose): (■) 200, (■) 100, (■) 50, (■) 25 and (■) 0 pg ml '. Platings
were done in triplicate.
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Chapter 4

Cloning of a bacteriophage-derived peptidase CHAPk into
Lactobacillus paracasei
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Abstract
CHAPk (cysteine/histidine-dependent peptidase) is a highly active enzymatic domain
from the endolysin associated with staphylococcal bacteriophage K, which is active against S.
aureus including MRSA and MSSA. The aim of this study was to establish a model whereby
an intestinal Lactobacillus could be made to secrete a bacteriophage endolysin exploiting the
secretion system associated with the bacteriocin, pediocin produced in Pediococcus
acidilactici. This study describes the cloning of the CHAPk gene into the pediocin operon in
Lactobacillus paracasei. Three constructs were designed containing different gene
combinations in the LactococcuslLactobacillus vector pNZ44. The first construct was
comprised of the CHAPk gene linked with the bacteriocin genes pedA, pedB, pedC and pedD.
The second was a copy of the first, but with the native pediocin operon ribosomal binding site
upstream of pedA. The third construct was made without the start codon of the CHAPk gene,
imitating the sequence of pediocin in the Pediococcus plasmid pSRQl 1. Crude extracts and
supernatants of each of these constructs were examined by SDS-PAGE for the presence of
recombinant CHAPk from Lb. paracasei.
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Introduction

Endolysins are enzymes with lytic activity against bacterial cells targeting either the
peptidoglycan or the sugar moieties of their cell walls. The lytic efficiency of these enzymes
has been demonstrated in both in vitro and in vivo conditions. The secretion of these lytic
enzymes by Generally Recognized as Safe (GRAS) bacteria has been determined as one of
their possible applications. Lactic acid bacteria belong to the normal human gut flora and a
number of these, such as Lactococcus lactis, have been successfully engineered in order to
produce vaccines (Haffiny et ah, 2007; Nouaille et ah, 2003) and cytokines (Steidler et ah,
2000) in the gastrointestinal tract (GIT). As a result, the prevention of infections using the
secretion pathway of lactic acid bacteria for endolysins is a potential application (RodriguezRubio et ah, 2012; Mayer et ah, 2008; Gaeng et ah, 2000). A pNZ8048-derived vector,
namely pNZ44, using the lactococcal constitutive promoter P44 has been previously designed
for the study of artificially acquired resistance of L. lactis against three different phages from
the P335 group (McGrath et ah, 2001). Lactobacillus paracasei is a lactic acid bacterium that
belongs to the normal flora of the human GIT. This bacterium has been used for the
production of exopolysaccharide beta-glucan, responsible for many different health-related
advantages, to be endogenously released in the human gut using the pediocin operon
secretion system within pNZ44 (Stack et ah, 2010). Pediocin is a bacteriocin produced by
Pediococcus acidilactici, through the pediocin operon, responsible for elimination of most
lactic acid bacteria and also of a number of Gram-positive bacteria (Klaenhammer et ah,
1993). The operon is comprised of four genes pedA, pedB, pedC and pedD involved in
pediocin production, secretion and immunity (Venema et ah, 1995). In this study, we used the
combination of the pediocin operon and the CHAPk gene within the high-copy pNZ8048derived plasmid pNZ44 for continuous secretion of the lytic enzyme using Lh. paracasei.
Material and methods

Bacterial strains
Cultures of E. coli XL 1-Blue carrying the CHAPk gene within the expression vector
pQE-60 (Qiagen, Hilden, Germany) were grown at 37 °C overnight in LB broth (Sigma
Aldrich, St Louis, Missouri, USA) with 100 mg mh' ampicillin (Sigma). P. acidilactici was
cultured in MRS broth (Sigma) at 37 °C. Lh. paracasei NFBC 338 is a bacterium isolated
from the human gastrointestinal tract during surgery and was obtained from the Moorepark
Food Research Centre (Teagasc, Fermoy, Cork, Ireland). This bacterium was grown at 37 °C
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in MRS broth (Sigma), with 5 jig ml'* chloramphenicol after transformation by
electroporation.
Constructs
Three different constructs were cloned into pNZ44. The first construct was comprised
of the pedA and CHAPk genes and of the genes pedB, pedC and pedD (Fig. 1). The second
construct was comprised of the same gene combination and the ribosome-binding site was
added upstream of the pedA gene (Fig. 2). The third construct used the same organisation as
the first construct except that the start codon ATG was discarded, leaving only one start
codon at the 5'-end of the pedA gene for the resulting SOEing product (Fig. 3).
DNA manipulation
The different gene amplifications were carried out with a high-fidelity enzyme KOD
Hot Start (Novagen, Madison, USA) using the supplier recommendations and the different
primers used are listed in Table 1. Genes pedA and CHAPk were amplified following the
Splicing by Overlap Extension technique (SOEing) described by Horton et al. (1993). The
pedA gene was amplified from pSRQl 1, from Pediococcus acidilactici, with forward primer
PedA-F, integrating the Ncol restriction site at its 5'-end, and with the reverse primer PedA-R
comprising an overhang at its 3'-end of 19 nucleotides corresponding to the 5'-end of the
CHAPk gene. Amplification of the CHAPk gene was performed with the forward primer
CHAP-F containing an overhang at 5'-end of 19 nucleotides, corresponding to the 3'-end
nucleotides of the gene pedA sequence, and its reverse primer CHAP-R, which integrated the
PstI restriction site. Both PCR products were diluted 1:100 and used as template (1:1 ratio)
for a new PCR reaction with PedA-F and CHAP-R primers. PCR product concentrations
were determined after amplification (Nanodrop Spectrophotometer ND-1000), and these were
run on agarose gels with the appropriate ladder (Bioline, London, UK). Both SOEing
products of CHAPk with PedA and the plasmid pNZ44 were subsequently digested with
enzymes Ncol and PstI (Roche) at 37 °C for two hours. Ligation (T4 DNA Ligase, Bioline,
USA) was carried out using a ratio insert:vector of 4:1 following the supplier’s protocol.
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Table 3. List of primers used in the study.
Name

Sequence (5'-3’)

PedA-F*

acatccatggatgaaaaaaattgaaa (pPHl, pPH3)

RBS-PedA-F*

acatccatgsaasaaEaassasattttts (dPH2)

PedA-R

ctgcttgSLgtcttagccaVdccaccaatgatattggcc (pPH 1, pPH2, pPH3)

CHAPk-F

ggccaatatcattggtggtdtggcVddgdctcddgcdg (pPH 1, pPH2)

CHAPk-F2

ggccaatatcattggtggtgctddgdctcddgcdg (pPH3)

CHAPk-R**

gcacctgcagtgcttttacaggtatttc (pPH 1, pPH2, pPH3)

PedB-F**

gcacctgcagcattatgctgagctggcatc (pPHl, pPH2, pPH3)

PedD-R***

gcacgglaccgcgaggattt (pPHl, pPH2, pPH3)

*primers have an Ncol- restriction site; **primers have a Pstl-restriction site; ***primer has a Kpnl-restriction
site; Ribosome Binding Site (RBS) is underlined with primer “RBS-PedA-F” sequence.

Transformation of E. coli TOP 10 cells
Vials of chemically competent E. coli TOP 10 cells (Invilrogen™, USA) were thawed
on ice and 5 pi (final total DNA concentration: 200 ng pp') of the ligation product was
injected into a vial. The vial was put on ice for 30 min. and the cells were heat-shocked at 42
°C for 30 s. The vial was put back on ice for two min. 250 pi of pre-warmed SOC medium
was added to the cells and the vial was placed in the incubator with shaking at 225 rpm for
one hour at 37 °C. The transformed E. coli cells were spread on LB agar plates with 10 pg
mk’ of chloramphenicol, and these were incubated at 37 °C overnight. The resulting colonies
that grew on plates were confirmed by amplification of the multiple cloning site by PCR.
Transformation of Lb. paracasei
Positive E. coli clones with pNZ44 and insert were grown in LB broth (10 pg ml'' of
chloramphenicol), and their plasmid was extracted (Qiaprep® Spin Miniprep Kit, Qiagen,
USA) to get a concentration of 200 ng pp'. GS-MRS broth was made up by mixing 13.75 g
of MRS broth powder with 12.5 g of glycine, 34.2 g of sucrose and 2.5 g of glucose.
Deionised water (250 ml) was added and the mix was autoclaved. SGWB washing buffer was
made up by mixing 85.5 g of sucrose with 50 ml of 100% glycerol. Deionised water (500 ml)
was added and the mix was autoclaved at 121 °C for 15 min. Lb. paracasei was inoculated in
MRS broth and incubated at 37 °C overnight anaerobically. A following inoculation (10%) in
GS-MRS broth was carried out with incubation at 37 °C overnight. Another 10% inoculation
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was carried out in fresh GS-MRS broth, which was subsequently incubated at 37 °C
anaerobically up to an OD^oo of 0.3. The culture was centrifuged at 4,000 x g at 4 °C for 20
min and the resulting cell pellet was washed with ice-cold SGWB buffer. These steps were
repeated another three times with all media kept at ice-cold temperature. The resulting
washed culture was suspended in 2 ml of SGWB.

The pNZ44 vector (1 pg) was

electroporated (GenePulser Xcell, Biorad) (2 kV/cm, 200 Q, 25 uF) within Lb. paracasei
using ice-cold 2 mm-gap cuvettes (VWR, USA). Cells were regenerated in 1 ml of pre
warmed MRS broth with 20 mM MgCU and 2 mM CaCU for two h at 37 °C. Lb. paracasei
cells were spread onto MRS agar plates with 8 pg ml'' of chloramphenicol and incubated
overnight at 37 °C. The resulting transformed cells were checked by colony-PCR across the
multiple-cloning site.
Detection of CHAPr in culture supernatants by ion-exchange chromatography
Standard Operating Procedures (SOPs) have been established specifically for the
production of the CHAPr protein (see Chapter 2, this thesis). The supernatants of
transformed Lb. paracasei cultures in MRS broth with 8 pg ml'* of chloramphenicol were
tested for the presence of CHAPr protein using the AKTAsystem with ion-exchange
chromatography. The purified fractions obtained were pooled, desalted and examined by
SDS-PAGE.
Protein profiles from Lb. paracasei crude extracts
Overnight cultures of each construct were grown up in MRS broth with 8 pg ml'* of
chloramphenicol. The culture was centrifuged for 10 min at 6,500 rpm (lEC CL30R
centrifuge. Thermo Scientific). An amount of 15 U of mutanolysin and 250 pg of lysozyme
were added to 1 ml of the culture and incubated at 37 °C for one hour. The resulting lysates
were centrifuged at 6,500 rpm for 10 min. The pellet and the supernatant were transferred
into one eppendorf tube each. The pellet was resuspended in sterile deionised water and both
samples were examined by SDS-PAGE (see Chapter 1, this thesis).
Results
SOEing PCR of the CHAPk and PedA genes and cloning into E. coli TOP 10 cells
The conglomerate of genes PedB, PedC and PedD was amplified using primers that
integrate the PstI and Kpnl restriction sites. The 4-kb amplified fragment was double digested
with these enzymes and ligated to the double-digested plasmid pNZ44 to generate three
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different combinations of genes: pPHl, pPH2 and pPH3. Both the CHAPk and PedA genes
were successfully amplified and SOEd together (Figs. 5 and 6). The SOEing product (1 pg)
was double digested with restriction enzymes Pstl and Ncol at 37 °C for 2 h. The digested
SOEing PCR products were ligated to the double-digested plasmid pNZ44 (Fig. 6). The
different combinations successfully gave three different plasmids pPHl (Fig. 1), pPH2 (Fig.
2) and pPH3 (Fig. 3).
Transformation of E. coli TOP 10 cells
E. coli TOPIC cells were transformed and selected on LB agar containing 10 pg mb'
of chloramphenicol (Fig. 7). Positive clones were plated onto new LB agar plates containing
10 pg mb' of chloramphenicol and incubated at 37 °C overnight. The remaining positive
clones were stocked at -20 °C and grown in LB broth to isolate their plasmid to confirm the
presence of the insert (Fig. 8). All the extracted plasmids were digested with the restriction
enzyme Ncol. The multiple cloning sites of plasmids from positive clones containing the
insert were amplified and sequenced. The data verified the expected sequence for all three
constructs.
Transformation of Lh. paracasei
Lh. paracasei cells were transformed with 1.5 pg of plasmid from positive E. coli
clones. The positive clones from the electroporation were isolated again on MRS agar plates
with 8 pg mb' of chloramphenicol. Plasmid was extracted from the positive isolates and the
multiple cloning site was amplified. A PCR product of 4 kb was expected for the positive
clones (Fig. 9). The resulting amplified products were sequenced and the results confirmed
that no mutation occurred.
Detection of CHAPk by ion-exchange chromatography
Lh. paracasei 50-ml cultures, harbouring pNZ44 with the three different inserts, were
centrifuged at 6,500 rpm for 15 min and the supernatants were transferred to a new sterile
tube. The method previously described (Chapter 2, this thesis) was followed by mixing 3 ml
of supernatant with 2 ml of binding buffer. When the supernatant was purified, the real-time
graph for the three different constructs demonstrated peaks lower than 100 mAu (Fig. 10).
When overexpressed in E. coli, the levels of CHAPk for purification were between 200 and
400 mAu on average.
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Protein profiles from crude extracts of Lh. paracasei and from purified fractions by SDSPAGE.
The protein extraction from each construct presented similar results to the control
with Lh. paracasei containing pNZ44 without an insert. In these cases, it can be seen that the
CHAPk protein is not expressed intracellularly (Fig. 11). For the second and third constructs,
no band appeared in Lane 6, which means no protein was secreted even with pNZ44
containing the insert. However, for the first construct pPH 1, it can be noticed that a protein
with a molecular weight of approximately 101 kDa was purified by ion-exchange
chromatography. As the AKTAsystem was set with the optimal conditions for purification of
CHAPk, this means that this protein possesses the same isoelectric point as CHAPk- The fact
that this protein was purified from Lh. paracasei culture supernatants suggested that it may
correspond to CHAPk that had been subjected to an unusual conformation. Hence, this
protein was desalted, sterilised and tested on an overlay assay against S. aureus DPC5246.
No halo appeared after incubation at 37 °C, which demonstrated the lack of lytic activity for
this protein.
Discussion
Endolysins possess characteristics that can be exploited by secretion systems. Indeed,
the combination of their antibacterial properties and lactic acid bacteria from the gut may
give birth to new anti-infective probiotic strains. Gaeng et al. (2000) have been the first group
to successfully clone an endolysin targeting a pathogen {Listeria monocytogenes) into a lactic
acid bacterium. The staphylococcal endolysins LysK and LysH5 were also successfully
secreted using L. lactis (Rodriguez-Rubio et al., 2012; O’Flaherty et al., 2005). Among the
lactic acid bacteria, Lh. paracasei is also a bacterium that Martin et al. (2011) have studied
using different expression cassettes to successfully produce antibody fragments. The purpose
of this study was to establish a cloning system whereby an intestinal Lactohacillus could be
made to secrete a bacteriophage endolysin by exploiting the secretion system associated with
the dinii-Listeria bacteriocin, pediocin, which is produced by Pediococcus acidilactici
(Motlagh et al., 1994; Henderson et al., 1992). The vector chosen was pNZ44, which is the
construct that results from the replacement of the promoter PnisA from the plasmid pNZ8048
by the L. lactis chromosomal promoter P44. This vector has been previously used for the
cloning of phage resistance genes in L. lactis (McGrath et al., 2001). These studies highlight
the possibility for endolysins to be hypothetically secreted by such bacterial strains.
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The results obtained here demonstrated that the vector and/or the host for the
secretion of CHAPk did not produce the enzyme intra- or extracellularly with or without
presence of the native ribosome-binding site from the pSRQll. Venema et al. (1995)
described the functioning of the pediocin operon. The transcription of the operon results in
two different transcripts with a major transcript comprised of pedA, pedB and pedC and a
minor one, which includes these three genes with pedD. PedD is involved in prepediocin
processing. In this study, a protein was produced by the construct pPHl and purified using
the same conditions as the CHAPk enzyme. The protein was found to have a molecular
weight between 41.6 and 58.2kDa, which may correspond to a protein resulting from one of
the transcripts from the pediocin operon (Fig. 11). The hypothetical production of the major
transcript from pPHl, encompassing pedA, CHAPk, pedB and pedC, had a predicted
molecular weight of 53.6kDa and isoelectric point of 8.9 (CHAPk has an isoelectric point of
8.8). This suggests that the theoretical processing of the transcript by pedD is not being
fulfilled, which would explain the lack of lytic activity from this protein. Desmond et al.
(2004) demonstrated that the vector pGROl from pNZ8048 in L. lactis and pGR02 from
pMSP3535 in Lb. paracasei, both containing the groESL operon from Lb. paracasei NFBC
338, resulted in the production of GroESL-protein (57.4 kDa) after induction. This study
suggests that the vector pNZ8048 is more suited for L. lactis than Lb. paracasei, even in the
presence of the groESL operon from Lb. paracasei. The combination of the bacterium and
pNZ44 has proven its ability to produce beta-glucan, a health-promoting and prebiotic
exopolysaccharide (Stack et al., 2012). This study suggests that the nature of the recombinant
protein plays a key role in its own secretion. Indeed, the molecular weight and the 3Dconformation of a lytic enzyme will enable the protein to be active, and a modification of its
active site will involve a reduced efficiency. Nevertheless, two natural plasmids, namely
pCDOl and pCD02, from Lb. paracasei NFBC 338 have been isolated and sequenced
(Desmond et al., 2005). ORF19 from plasmid pCDOl shows homology to transporter proteins
from the transmembrane-spanning drug efflux family in which proteins from S. aureus, QacA
and QacB, are the most characterised (Paulsen et al., 1996; Rouch et al., 1990). The
hypothetical use of the expression cassettes studied by Martin (2011) used in either
chromosome or pCDOl plasmid from Lb. paracasei might be a solution for further studies of
this application of the CHAPk protein. In addition, the use of the groESL operon from Lb.
paracasei NFBC 338 can be used within pNZ44 with the CHAPk gene cloned instead of the
Gro-ESL protein-encoding gene. In addition, it has been reported that the pediocin AcH
secretion system is in Lb. plantaruni WHE92 (plasmid pWHE92) (Miller et al., 2004). The
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transfer of this plasmid into Lh. paracasei with the cloning of the CHAPk gene in place of the
pediocin gene may be a solution.
Figures

Figure 1. Map of pPHl, the first construct in vector pNZ44: pedA, CHAPk, pedB, pedC and pedD (53’).

Figure 2. Map of pPH2, the second construct in vector pNZ44: RBS, pedA, CHAP^, pedB, pedC and
pedD (5'-3').
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Figure 3. Map of pPH3, the third construct in vector pNZ44: peclA, CHAPn (ATG codon discarded),
pedB, pedC and pedD (5'-3').

Figure 4. Agarose gel (5%) electrophoresis showing the presence of the PedA gene generated using
primers with restriction sites incorporated in overhangs. Lane 1: “HyperLadder V” (Bioline), Lane 2:
64-bp PCR product {PedA gene with overhang).
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Figure 4. Schematic representation of the different steps for the construction of pPHl, pPH2 and
pPH3.

Figure 6. Agarose gel (1%) electrophoresis. Both gels have “HyperLadder I” in Lane 1. (A) Lane 2:
CHAPK gene with overhang (514 bp); (B) Lane 2: pedA + CHAPk SOEing product (569 bp), Lane 3:
extracted plasmid from positive transformed Lb. paracasei; Lane 4; double digestion of resulting
plasmid pPHl with Ncol and PstI restriction enzymes.
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Figure 4. E. coli TOP 10 cell transformation results; (A) plasmid pNZ44 alone; (B) no DNA; (C)
plasmid pNZ44 double digested and ligated; (D) plasmid pUC19supplied; (E) plasmid pNZ44 with
SOEing and PedB, PedC and PcdD inserts (pPHl).

Figure 8. Agarose gel (1%) electrophoresis showing plasmid extractions from E. coli TOP 10 cells
following ligation and transformation (pPHl). Lane 1: “HyperLadder 1” (Bioline); Lane 2: digested
control plasmid pNZ44 with the PedB, PedC and PedD genes (7,088 bp); Lane 3: digested plasmid
pNZ44 from transformed colony with control plasmid (7,088bp); Lane 4; digested plasmid pPHl
from transformed E. coli TOP 10 cells.
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Figure 9. Agarose gel (1%) electrophoresis showing the amplification of the multiple cloning site of
plasmid pNZ44 from four positive Lh. paracasei clones after electroporation. Lane 1: “HyperLadder
I”; Lanes 2 to 5; amplified multiple cloning sites from positive clones 1, 2, 3 and 4 comprising pedA,
pedB, pedC and pedD (4kb).

Figure 10. Purification curve on the AKTAprime automated purification system, using ion-exchange
chromatography. (A) crude cell lysate peak, (B) purified protein peak.
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Figure 51. SDS-PAGE showing protein profiles from Lb. paracasei. (A) pPHl construct: Lane 1:
Ladder (SDS-PAGL Standard, Broad Range, Biorad), Lane 2: Supernatant from lysed Lh. paracasei.
Lane 3: insoluble phase from transformed Lh. paracasei. Lane 4: Supernatant from lysed Lh.
paracasei with pNZ4-4 without insert. Lane 5: insoluble phase from Lb. paracasei with pNZ44
without insert. Lane 6: Lh. paracasei culture supernatant purified with the AKTAsystem, Lane 7:
purified CHAPk protein. (B) pPH2 construct: Lane 1: Ladder (same as above). Lane 2: supernatant
from lysed Lh. paracasei. Lane 3: insoluble phase from transformed Lh. paracasei. Lane 4:
supernatant from lysed Lb. paracasei with pNZ44 without insert. Lane 5: insoluble phase from Lh.
paracasei with pNZ44 without insert. Lane 6: Lh. paracasei culture supernatant purified with the
AKTAsystem, Lane 7: purified CHAPk protein. (C) pPH3 construct: Lane 2: supernatant from lysed
Lh. paracasei. Lane 3: insoluble phase from transformed Lb. paracasei. Lane 4: supernatant from
lysed Lb. paracasei with pNZ44 without insert. Lane 5: insoluble phase from Lb. paracasei with
pNZ44 without insert. Lane 6: Lh. paracasei culture supernatant purified with the AKTAsystem, Lane
7: purified CHAPk protein.
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Conclusion
Endolysins are lytic enzymes that degrade the peptidoglycan of the bacterial cell wall.
For the last decade, they have been studied in detail and have demonstrated interesting
characteristics, in some cases, in in vivo applications. In general, they possess a modular
structure with a binding domain and a catalytic domain. The catalytic domain can be of
various natures displaying glycosidase, amidase, endopeptidase or lytic transglycosylase
activity. The exogenous application of purified endolysins on bacteria will cause “lysis from
without” (Molineux et ah, 2006). A number of these lytic enzymes possess the ability to kill
either a narrow or a wide range of bacteria. It has been reported that the lytic efficiency of
these enzymes will depend on the nature of their activity and the chemotype of the
peptidoglycan of the bacteria. Indeed, certain bacteria share common features in their
peptidoglycan and a number of enzymes, which target a particular chemotype, such as the
chemotype Aly shared by a number of Gram-positives and Gram-negatives (Yuan et ah,
2012), can lyse a wide range of bacterial cells. To date. Gram-positive bacteria endolysins
have been the most explored and exploited because of their lack of outer-membrane, present
in Gram-negatives. Endolysin engineering offers a variety of possibilities in terms of lytic
activity (Mayer et al., 2011; Horgan et al., 2009; Briers et al., 2008) and enzyme stability
(Resell et al., 2011). In addition, the combination of these enzymes with other antibacterial
compounds is also an interesting outcome for the prevention of infections by requiring
multiple mutations from the bacteria to become endolysin-resistant. Endolysins, because of
their properties and antibacterial potential, may represent a promising alternative or
complimentary agent to antibiotics. CHAPk, a bacteriophage-derived cysteine/histidinedependent amidohydrolase peptidase from the endolysin LysK (from staphylococcal phage
K), is comprised solely of the 165 amino acids from the N-terminal catalytic domain of its
native enzyme (Horgan et al., 2009). This thesis reported the optimal conditions for the
production of CHAPk by establishing the standard operating procedures, and also the
potential applications of the enzyme in bovine blood and in a secretion system model in
Lactobacillus paracasei.
Chapter 2 described in detail the standard operating procedures for the production of
the CHAPk protein. This is now available for other researchers who may work on the
endolysin topic. The parameters for the culture of E. coli XL 1-blue clones, protein extraction,
ion-exchange chromatography, desalting, determination of the concentration and activity of
the enzymes are described. A total of twenty batches of two litres each resulted in a stock of
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CHAPk protein of 1.6ml at a concentration of 7,500pg ml' , giving a total quantity of 12mg
of enzyme with an activity of 189U mol '. The culture of clones as well as the purification
and sterilization of the enzyme were the critical steps of the production as waste of protein
CHAPk may occur. The results demonstrated to be consistent using the optimal conditions.
The CHAPk produced was subsequently used in the following experiment. Over the course of
the development of this procedure, many variables were adjusted to arrive at the optimal
protocol. While this is limited to the enzymes, whose biochemical properties (PI etc) are
similar to those of CHAPk, the method can certainly be further adapted to suit other proteins.
In Chapter 3, the CHAPk enzyme was applied to artificially-infected bovine blood to
assess its potential for the elimination of staphylococci in this immune-active environment.
One of the properties of blood is to naturally coagulate for the cessation of blood loss from a
damaged vessel. For the purpose of the experiment, disodium hydrogen citrate and glucose,
an anticoagulant agent, was added at different concentrations, namely 15, 10 and 5% (v/v).
The addition of anticlotting agent was varied in order to determine the impact of its
concentration on staphylococcal growth and anticoagulant effect on bovine blood. The
addition of 10% of disodium hydrogen citrate and glucose demonstrated to be the most
suitable for the experiment by allowing reasonable S. aureus growth while allowing the blood
to remain unclotted for two weeks. In the second part of the study, different concentrations of
the enzyme, namely 200, 100, 50 and 25 pg mP', were added to S. aureus-'infected blood.
When a concentration of 200 pg mp' of CHAPk was used, the S. aureus cells were killed
within 30 minutes. When a 100 pg mp' of enzyme was assessed, S. aureus cells were
eliminated within one hour. The delay in the elimination of staphylococcal cells in blood
compared to in broth was suggested to be linked to the presence of antibodies and other
active immune factors in the blood. This experiment is critical for the further development of
endolysin applications. Indeed to date, there are no other reports about anti-staphylococcal
endolysins efficacy in blood. These are a pre-requisite to clinical trials, which might be
planned. This type of work would also be complimented by the evaluation of presence of
inflammatory proteins in blood, which might be released by polymorphonuclear leucocytes
(PBMCs). Such work should be done as a follow up to the above experiment. Nevertheless,
the results observed for the pg mP' of CHAPk in blood are very promising.
The aim of the study reported in Chapter 4 was to attempt to establish a model
secretion system for endolysins in lactic acid bacteria namely Lactobacillus paracasei, using
the CHAPk gene in combination with the pediocin operon in pnZ44. The vector pNZ44 is
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derived from the replacement of the native promoter PnisA of pNZ8048 by the chromosomal
promoter from Lactococcus lactis P44 for (McGrath et ah, 2001). In this study, different gene
combinations were used where CHAPk was cloned in pediocin operon as described by Stack
et al. (2010) namely pPHl, with a ribosome-binding site upstream pedA (pPH2) and without
ATG start codon in the CHAPk gene, imitating the native sequence from pediocin (pPH3).
Cells crude extracts and culture supernatants were examined by SDS-PAGE to detect
presence of secretion of the protein. No CHAPk protein was detected from any construct.
However, a protein with a higher molecular weight than CHAPk was purified from the
supernatant from Lb paracasei culture with pPHl, and this suggested that this protein
possessed similar isoelectric point to CHAPk. The resulting purified protein was tested
against S. aureus DPC5246 with no lytic effect unfortunately. The hypothetical use of the
expression cassettes studied by Martin (2011) used in either chromosome or pCDOl plasmid
from Lh paracasei might be a solution for further study on this application of the CHAPk
protein. In addition, the use of groESL operon from Lh paracasei NFBC 338 can be used
within pNZ44 with the CHAPk gene cloned instead of the Gro-ESL protein gene. In addition,
it has been reported that pediocin AcH secretion system is in Lh plantarum WHE92 (plasmid
pWHE92) (Miller et al., 2005). The transfer of this plasmid into Lh paracasei with the
subsequent cloning of the CHAPk gene at the place of the pediocin gene may be a solution.
The work conducted in this chapter nevertheless did set a foundation for future approaches
for developing secretion systems for endolysins, which may have an application in the
gastrointestinal tract.
In conclusion, a wide range of techniques were learned over the course of this project.
Protocols establishing the optimal conditions for the CHAPk production were used and the
resulting yields were determined. These optimal conditions may provide a basis of work for
hypothetical high-scale production of the enzyme. In addition, CHAPk has been applied to
infected blood and while the cloning into the secretion system did not lead to success, the
complexity of the approach was appreciated. The important data obtained in the blood work
set a basis of knowledge for further work. Indeed, the level of cytokines and antibodies are
involved in the antibacterial process in humans, and it is worthy to assess the incidence of
injection of such protein within human blood. Such study would aid in determining whether
the CHAPk protein is a potential safe alternative to antibiotics for the treatment of S. aureus
infections. Concerning the model of secretion system, it is worthy to consider other
parameters. The resulting constructs pPH 1, pPH2 and pPH3 may be assessed in another lactic
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acid bacterial strain or the vector may be changed. Also, the P44 promoter may be replaced
by different promoters where high yields of protein production were detected (Mijakovic et
ah, 2005). The idea of developing a probiotic with wide-range of antibacterial properties is
one of the most interesting outcomes for endolysins.
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